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Intermittent neurogenic claudication (INC) is a complex of symptoms caused by 
degenerative lumbar spinal stenosis (LSS). 1 The disease was first described by 
Van Gelderen in 1948 and Verbiest in 1950.1-4 The characteristic symptoms are leg 
pain (frequently both legs), which can be exacerbated with prolonged walking 
and standing and/or lumbar extension, and associated back pain.1-4  As in other 
acquired diseases, INC is usually seen in the elderly.1, 5 Severe stenosis is common 
in elderly spine: 30.4% in the population have a severe stenosis (average age 67.3).5 
However, only 17.5% of them have typical INC symptoms.
Diagnosis and imaging techniques:
The explanation of the symptoms is often disputed: Verbiest et al stated that 
the narrowing of the canal (due to degenerative tissue) leads to compression 
of the nerves and therefore causes symptoms of nerve impairment.4 Measuring 
the diameter of the lumbar spinal canal was the main tool to diagnose LSS and 
subsequently INC. Verbiest started in the 1950s with in vivo measuring techniques.4 
In the 1960s Evans described a complete cerebral spinal fluid stop, on myelography, 
at the lower lumbar levels in patients with intermittent neurogenic claudication.1 
Imaging techniques were used, after that discovery, preoperatively to select 
patients for surgical treatment. First myelography was used to prove a complete 
spinal fluid stop and later Computer Tomography images were used. Nowadays 
Magnetic Resonance (MR) imaging techniques are used to select patients with 
INC for treatment.6 Many different grading scales (such as the Schizas scale) exist 
to differentiate between mild and severe lumbar spinal stenosis on MR images. 
Nevertheless, good prospective studies have not been performed to assess the 
effectiveness and quality of MR imaging techniques and stenosis grading scales.6
Surgical treatment:
Surgical treatment is considered to be the gold standard for patients with INC caused 
by LSS.1-4 However, the first prospective comparative study proving that surgical 
therapy was superior in comparison to conservative treatment was published in 
2007.7, 8 The first technique that was described to widen the lumbar spinal canal 
was wide bony decompression (laminectomy).9 Until today this technique is 
widely used. However since, INC is often accompanied by back pain, and thus to 
postoperative back-pain, it is hypothesized that a wide decompression is a ground 
for potential instability. Therefore, less invasive techniques, such as laminotomy 
(partial removal of the lamina), were developed and implemented.10-12 




Nevertheless, long-term clinical results after surgery are quite poor: only 64% of the 
patients are satisfied after surgical treatment.13 Numerous patients still complain 
about back pain after surgery. In order to solve this ‘problem’, a French group 
introduced a new, non-rigid fixation for patients with LSS and associated back pain 
in 1984: the Wallis system.14-16  It was a new idea to implant non-rigid implants to 
indirectly decompress the lumbar canal and to ‘unload’ the facet joints. The idea 
was based on their experience of implanting non-rigid implants in other joints. 
The Wallis system was first implanted in 1986.14, 15 Nowadays, (other) interspinous 
process devices (IPDs) are used in the treatment for LSS and also others for back 
pain.17-19 The X-stop and Coflex implants were first used in the USA in an FDA trial.17 
In contrast, in the European countries surgeons started to implant these devices 
right away (not in any prospective study design).14, 15 As a result, these implants are 
widely used for almost 30 years to treat patients with INC caused by LSS. 
Objective and outline of this thesis
The main objective of this thesis is to compare bony decompression with 
implantation of interspinous process devices (IPDs) in patients with intermittent 
neurogenic claudication (INC) caused by lumbar spinal stenosis (LSS). At the start 
of this research project, no double blind randomized study on this subject was 
published. However, implantation of IPDs was already part of the daily practice in 
some Dutch neurosurgical and orthopedic clinics. In chapter 2 a national survey 
among Dutch spine surgeons is presented about the usual care of patients with 
intermittent neurogenic claudication caused by lumbar spinal stenosis. Surgeons’ 
expectations of different treatment options are presented. The existing evidence on 
interspinous implant surgery will be systematically reviewed in chapter 3. Results 
of treatment with IPDs are compared with other (conservative) treatment options. 
In chapter 4 the design of the Foraminal Enlargement Lumbar Interspinosus 
distraXion (FELIX) trial is described. This double-blind, multicenter, randomized 
(cost)effectiveness study was designed to answer the question whether treatment 
with IPDs would be more (cost) effective compared with conventional bony 
decompression. Short-term results (eight weeks), long-term results (one year) and 
results in different subgroups are described in chapter 5. The two-year results are 
presented in chapter 6. The analysis based on total direct and indirect costs of 
both procedures (treatment with IPD and bony decompression) are presented in 
chapter 7.
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Measuring the amount of lumbar stenosis via estimating the compression on lumbar 
magnetic resonance imaging is now considered standard in the preoperative 
work-up in patients with INC suitable for surgical treatment. However, correlation 
between baseline clinical complaints and the compression on MR images has never 
been evaluated. Furthermore, the prognostic value of compression on MR images at 
baseline for the extent of possible recovery at long-term clinical follow-up is also not 
known. Results of the degree of compression on MR images compared with clinical 
functioning at baseline and long-term follow-up are presented in chapter 8.
Without any good prognostic evidence, new devices have been implanted to 
treat patients with INC. Drugs are introduced using robust introduction models. 
However, it is possible to use spinal implants in patients without any good clinical 
evidence. Ethical considerations of the introduction of these devices are presented 
in chapter 9. 
Summary and conclusions are presented in chapter 10 in English and in chapter 
11 in Dutch.
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Background Various surgical and nonsurgical treatments for lumbar spinal stenosis 
(LSS) are widely adopted in clinical practice but high quality randomized controlled 
trials to support these are often lacking, especially in terms of their relative benefit 
and risk compared with other treatment options. Therefore, an evaluation of 
agreement among clinicians regarding the indications and the choice for particular 
treatments seems appropriate.
Methods One hundred six Dutch neurosurgeons and orthopedic spine surgeons 
completed a questionnaire, which evaluated treatment options for LSS and 
expectations regarding the effectiveness of surgical and non-surgical treatments.
Results Responders accounted for 6971 decompression operations and 831 spinal 
fusion procedures for LSS annually. Typical neurogenic claudication, severe pain/
neurologic symptoms, and a pronounced constriction of the spinal canal were 
considered the most important indications for surgical treatment by the majority of 
responders. Non-surgical treatment was generally regarded ineffective and believed 
to be less effective than surgical treatment. Interlaminar decompression was the 
preferred technique by 68% of neurosurgeons and 52% orthopedic surgeons for 
the treatment of LSS. Concomitant fusion was applied in 12% of all surgery for LSS. 
Most surgeons considered spondylolisthesis as an indication and spinal instability 
as a definite indication for additional fusion.
Conclusions The current survey demonstrates a wide variety of Dutch spine 
surgeons’ preferred treatment of symptomatic LSS. To minimize variety, national 
and international protocols based on high-quality randomized controlled trials and 
systematic reviews are necessary to give surgeons more tools to support everyday 
decision-making.
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Introduction
Lumbar spinal stenosis (LSS) is the most common reason for lumbar surgery among 
people over the age of 65 [10]. Surgery rates of LSS have increased markedly over 
the past decade [35]. The incidence of lumbar surgery for in the United States of 
America was 1.4 per 1000 and patient costs amounted nearly 1.65 billion US dollars 
in 2009 [10]. In comparison, the annual incidence of lumbar surgery for LSS in the 
Netherlands was 0.9 per 1000 according to Dutch hospital payment data in 2007. 
A recent meta-analysis of randomized controlled trials concluded that surgical 
decompression with or without fusion, or implantation of interspinous process 
devices (IPD) is more effective than non-surgical treatment [21, 36]. The gold standard 
surgical treatment of symptomatic LSS is a facet-preserving laminectomy [13]. More 
recently, less invasive techniques such as a unilateral and bilateral laminotomies, 
spinous process osteotomies and indirect decompression with IPDs, have been 
developed to minimize tissue damage and prevent surgery-induced instability [3, 
6, 12, 14, 24, 28, 30, 37, 38]. In cases of severe spinal deformity and marked instability, 
concomitant fusion procedures may be necessary [20]. Currently, various surgical 
and non-surgical treatments are widely adopted in clinical practice but high quality 
randomized controlled trials to support these are often lacking, especially in terms 
of their relative benefit and risk compared with other treatment options. Various 
authors state that the lack of evidence is reflected by large geographic variation 
of spine surgery rates and choices for particular surgical procedure [4, 7, 9, 10, 35]. 
Therefore, an evaluation of agreement among clinicians about the indications and 
the choice for particular treatments seems appropriate. Accordingly, a survey on 
the management of patients with LSS was conducted among neurosurgeons and 
orthopedic spine surgeons in the Netherlands.




In 2011, all 195 neurosurgeons of The Netherlands Neurosurgeon Association 
and orthopedic surgeons of the Dutch Spine Society, were asked to fill in a 
questionnaire. Subjects who did not respond were sent a reminder after 2 months. 
The questionnaire referred to various aspects of the treatment of symptomatic LSS. 
The questionnaire consisted of 22 questions regarding: 1) Surgeons’ characteristics: 
age, sex, years of clinical experience and number of annually performed surgical 
procedures for LSS; 2) Preferred surgical technique and use of concomitant 
fusion or indirect decompression with IPD’s; 3) Perceived effectiveness, severity 
of postoperative low back pain and complication incidence of various surgical 
techniques; 4) Considerations for surgery; 5) Effectiveness of non-surgical treatment; 
6) Considerations for non-surgical treatment. On six items we asked the surgeon’s 
opinion according to a 5-point Likert scale, ranging from ‘least’ to ‘most’ or ‘worse’ to 
‘excellent’. For the analysis, these five categories were reduced to three, by merging 
the opposite categories and retaining the intermediate/neutral category. Data 
were analyzed using descriptive statistics. Comparisons were made using a t-test 
in case of continuous outcome data and a chi-square test in case of categorical 
data. All frequencies were based on the total number of valid responders. IBM SPSS 
software, version 20.0, was used for all statistical analysis. 
Results
Surgeons’ characteristics
106 out of 195 questionnaires were returned (response rate 54%). Among the 
responders there were 102 male and 4 female surgeons. The majority of the 
responders were neurosurgeon (62%). 
The median clinical experience of the responding neurosurgeons and orthopedic 
surgeons was 13.2 years. On average the responding neurosurgeon performed 82 
decompressions annually, compared with 41 decompressions by orthopedic spine 
surgeons (p=0.001, t-test). The responders performed a total of 6971 decompression 
operations annually (Table 1).
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Table 1. Baseline characteristics. 
Responder’s characteristics Number of responders (%)
Number of responders  106 of 195 (54%)
Male 102 (96%)
Neurosurgeon 66 (62%)
Orthopedic surgeon 40 (38%)
Years of experience 13.2 – Interquartile range (IQR) 14
Number decompressions/year
0-10    14 (13.2%)
11-25    14 (13.2%)
26-50    31 (29.2%)
51-75 11 (10.4%)
76-100    18 (17.0%)
>100
    
18 (17.0%)
Perform (occasional) concomitant fusion procedures
0   48 (45.3%)
1-10    31 (29.2%)
11-20    18 (17.0%)
21-30    6 (5.7%)
>30    3 (2.8%)
Indications for surgery and effectiveness of non-surgical treatment
Typical neurogenic claudication, severe pain/symptoms and a pronounced 
constriction of the lumbar spinal canal were considered the most important 
indications for surgical treatment by more than half of responders (figure 1). 43% 
of the responders required failure of non-surgical treatment before scheduling 
surgery among all cases of LSS. 33% required prior non-surgical treatment only in 
case of mild symptoms or moderate severity of stenosis, and 25% did not require 
prior non-surgical treatment at all. The majority of responders required 3 months 
of adequate non-surgical treatment (55%), whilst 17% required non-surgical 
treatment for at least 6 months. As part of the non-surgical treatment regime, pain 
medication was most frequently reported as effective (31% of responders). Physical 
therapy, counseling by the general practitioner or neurologist, epidural injections, 
and the use of an orthosis were generally regarded ineffective (Figure 2). Non-
surgical treatment was regarded most effective among subjects <70 years, whilst 
symptoms refractory to prior decompression, long-lasting symptoms, concomitant 
spondylolisthesis, and multiple level stenosis were regarded to be associated with 
worse treatment outcome (Figure 3).




Both neurosurgeons (68%) and orthopedic surgeons (52%) preferred an interlaminar 
decompression in most cases of LSS (Figure 4). 
Figure 4. Surgeons’ preferred technique to treat patients with LSS
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A t tal lamine tomy was the preferred technique in 24% of responders and 
a laminectomy including medial facetectomy was the preferred technique in 
19% of responders. Only one orthopedic surgeon regularly performed indirect 
decompression with IPDs and one orthopedic surgeon routinely used IPDs in 
addition to conventional decompression. Endoscopic laminotomy was performed 
by only 4% of responders. Unilateral laminotomy was the preferred technique in 
30% of orthopedic spine surgeons compared with 6% of neurosurgeons (p=0.001). 
Bilateral laminotomy was the preferred technique in 25% of orthopedic spine 
surgeons compared with 12% of neurosurgeons (p=0.001). Other differences 
regarding preferred techniques among neurosurgeons and orthopedic surgeons 
were not significant. 
Expectations for surgical outcome
The surgeons’ expectations regarding the effectiveness of surgery, postoperative low 
back pain severity, and complication incidence of different lumbar decompression 
techniques are listed in Table 2. Laminectomy, including medial facetectomy, 
and interlaminar decompression were expected to be most effective (83% of 
surgeons), whereas IPD and endoscopic laminotomy were expected to be least 
effective (54 and 51% of surgeons, respectively). Most postoperative back pain was 
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expected after laminectomy with medial facetectomy and laminectomy without 
medial facetectomy (36% and 25% of surgeons, respectively), and least after IPD 
and endoscopic laminotomy (80% and 77% of surgeons, respectively). Surgical 
complications were expected to be highest with laminectomy including medial 
facetectomy and endoscopic laminotomy (19% and 14% of surgeons, respectively) 
and lowest with interlaminar decompression laminectomy, unilateral or bilateral 
laminotomy and IPD (82, 81, 80 and 92% of surgeons, respectively). Overall, 
surgeons expected a satisfactory outcome of 76% after lumbar decompression for 
LSS at short-term follow-up (8 weeks) and 65% at long-term follow-up (5 years). 
Table 2. Surgeons’ expectations about the results of different lumbar decompression techniques. 
Expected effectiveness Expected low back pain Expected complications
most neutral least most neutral least most neutral least 
Laminectomy including 
medial facetectomy
83.3 7.1 9.5 36.0 34.8 29.2 19.3 19.3 61.4
Laminectomy 67.9 17.9 14.3 25.3 42.2 32.5 7.2 26.5 66.3
Interlaminar decompression 83.0 13.6 3.4 6.8 29.5 63.6 1.1 17.0 81.8
Unilateral laminotomy 58.8 19.1 22.1 9.0 26.9 64.2 2.9 15.7 81.4
Bilateral laminotomy 52.2 21.7 26.1 14.3 27.1 58.6 5.6 14.1 80.3
IPD 20.3 25.4 54.2 6.6 13.1 80.3 4.7 3.1 92.2
Endoscopic laminotomy 25.6 23.3 51.2 5.9 17.6 76.5 14.0 17.5 68.4
The numbers shown are percentages of valid responses. IPD; interspinous process devices.
Table 3. Indirect decompression with IPDs.
Number of responders (%)
Number of surgeons performing operations with IPD 33 (31%)
Number of operations with IPD annually 303
Indication for IPD placement 
· Neurogenic claudication 29 (88%)
· Low back pain 2 (6%) 
· Lateral foramen stenosis 13 (39%)
· Part of a rigid fixation 1 (3%)
· Part of a dynamic fixation 3 (9%)
· After discectomy with herniated disc 2 (6%)
Implant used
· Coflex 19 (58%)
· X-stop 4 (12%)
· Aperius 5 (15%)
· Diam 2 (6%)
· ISS 2 (6%)
· other 1 (3%)
IPD; interspinous process devices.




58 of the 106 responders performed concomitant fusion procedures if deemed 
necessary, of which 49.2% were neurosurgeon and 65.0% orthopedic surgeon 
(p=0.115). These 58 surgeons annually performed 831 spinal fusion procedures for 
LSS. Additional fusion was required in 12% of 6971 procedures for LSS in our survey. 
Additional fusion was deemed necessary in the presence of spondylolisthesis grade 
2 or more and documented spinal instability by 79.3% and 74.1% of respondents, 
respectively. Only 24.1% considered fusion necessary in the presence of low back 
pain, and 17.2% in case of isthmic spondylolisthesis without instability. 58.6% of 
responders considered fusion in case of spondylolisthesis grade 1. 
Figure 1. Indications for surgical treatment
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Frequency an  indications for indirect decompression with IPDs
33 spinal surgeons (33%) performed indirect lumbar decompression with IPDs. 
They accounted for a total of 303 IPD implantations annually, among a total of 
6971 procedures for LSS in our survey. This number does not include the use of 70 
IPDs within study protocols [23]. Neurogenic claudication was the most frequent 
indication for treatment with IPD (Table 3). 
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Figure 2. Effectiveness of conservative treatment
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Figure 3. Predictive factors for good outcome  
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The results of our survey among Dutch neurosurgeons and orthopedic surgeons 
reflect the current clinical management of patients with LSS in the Netherlands. 
Typical neurogenic claudication and severe pain/symptoms were considered 
the most important indications for surgical treatment by nearly all responders. In 
agreement with literature, these symptom characteristics are considered important 
predictors of good outcome of surgical treatment [19, 25]. The extent of stenosis 
was regarded as an important indication for surgery by slightly fewer responders. 
Accordingly, previous surgical studies have demonstrated a significant correlation 
between good treatment outcome and a pronounced constriction of the spinal 
canal [2, 15, 16]. Conversely, the duration of symptoms [16, 27] and the presence 
of comorbid conditions (i.e. cardiovascular, diabetes, and hip joint arthrosis) [2, 11, 
18] negatively influence the results of decompression surgery. 
Limited evidence is available regarding the efficacy of non-surgical treatments 
in patients with LSS [33, 34]. Nonsurgical treatments have most frequently 
been compared with other treatments, rather than to the natural course of LSS 
[31]. Currently, the choice of treatment is mainly guided by clinical judgment, 
observational studies, and in analogy to other spine studies. Physical therapy, 
pain medication, epidural injections, orthosis, and counselling are widely adopted 
in the current clinical practice, despite questionable evidence of their efficacy. 
The responders in our survey reported the effectiveness of these non-surgical 
treatment strategies to be generally low and predictors of non-surgical treatment 
outcome varied considerably. Complaints refractory to prior decompression, long-
lasting symptoms, concomitant spondylolisthesis, and multiple level stenosis were 
associated with bad non-surgical treatment outcome according to the majority of 
the responders.
The most commonly performed surgical technique for the treatment of LSS was 
interlaminar decompression. As narrowing of the spinal canal predominantly 
takes place at the interlaminar region involving the facet joints and ligamentum 
flavum, resection of the whole lamina may not always be necessary to effectively 
decompress the spinal canal [8, 29]. Recent publications documented the use 
of even less invasive techniques that avoid the removal of midline structures 
(spinous processes and inter- and supraspinous ligaments), which are designed 
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to preserve spinal integrity, through minimizing the disruption of back muscles 
and the posterior ligaments [6, 12, 14, 26, 30, 37]. These studies reported favorable 
treatment outcomes and post-operative low back pain of (endoscopic) unilateral 
and bilateral laminotomy compared with conventional laminectomy, and no 
significant differences regarding the incidence of postoperative complications 
[6, 12, 14, 26, 30, 37]. In contrast to the findings of these studies the expected 
effectiveness of these techniques was lower than of conventional midline 
decompression techniques in our survey. Possibly, the small patient populations 
and generally poor methodologic quality of these studies caused this discrepancy. 
Further, laminotomy as opposed to laminectomy may not be suitable to all patients 
with LSS. In cases of extensive stenosis on MRI or intraoperative doubt of adequate 
decompression it may be necessary to perform a laminectomy [26]. Therefore, 
results from studies which compare the results of laminotomy with laminectomy 
should be interpreted cautiously [26]. Nevertheless, it seems appropriate to tailor 
the technique for decompression to the severity of stenosis. The reported long-
term effectiveness of surgery in our survey (65% satisfactory outcome after 5 years) 
was in agreement with the pooled estimate of a meta-analysis, which documented 
a long-term satisfactory outcome after surgery in 64% of the patients [32]. 
In our survey, 58 (55%) surgeons performed 831 fusion procedures in patients with 
LSS annually. This amounts to 12% of all 6971 procedures for LSS in our survey. Deyo 
et al. reported that the rate of spinal stenosis surgery in the Medicare population 
remained stable, but the rate of concomitant fusion procedures increased 15-
fold to 15% of all surgery for spinal stenosis in the period 2002-2007 [10]. These 
concomitant fusion procedures were independently associated with increased 
perioperative mortality, major complications, rehospitalization and costs, and 
therefore should only be performed when necessary. However, the indications 
for additional spinal fusion are often unclear [20], and occasionally surgeons’ 
preferences may outweigh patients’ and disease characteristics in the choice 
of surgical procedures [5, 17]. Concomitant fusion procedures were deemed 
necessary in the presence of spondylolisthesis grade 2 or more by 79.3% of 
responders, and documented spinal instability by 74.1% of responders. Low back 
pain as an indication for fusion is controversial [1], and was reported by 24.1% of 
the spine surgeons. Thirty-one percent of the responders occasionally performed 
indirect decompression with IPDs, despite limited evidence to support this surgical 
treatment [22]. Previous randomized controlled trials compared the effectiveness 
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of decompression with IPDs with nonsurgical treatment, rather than conventional 
decompression [3, 38]. Only recently, a randomized controlled trial comparing 
decompression with IPDs with conventional midline decompression reported 
no advantage of decompression with IPDs over conventional decompression. 
Moreover, a significantly increased reoperation rate among patients treated with 
IPDs was reported [24]. 
The present study is subject to several limitations. Spine surgeons’ responses 
may be subject to a recall bias and reliability regarding controversial subjects in 
particular (e.g. indications for concomitant fusion, use of IPDs) cannot be assured. 
Definitions of surgical techniques were not provided in detail, which may result in 
misclassification or heterogeneity amongst the techniques reported. Furthermore, 
106 out of 195 spine surgeons completed the questionnaire, thus our data may 
not be representative for all neurosurgeons and orthopedic spine surgeons in the 
Netherlands. 
The current survey demonstrates a wide variety of Dutch spine surgeons’ preferred 
treatment of symptomatic LSS. The observed variation reflects the limited available 
evidence regarding the effectiveness of non-surgical treatment, the effectiveness 
of various surgical techniques, and indications for concomitant fusion. Generally, 
failure of non-surgical treatment was considered as a pre-requisite to a surgical 
procedure to be performed, but paradoxically non-surgical treatment was 
often regarded ineffective. Surgeon’s expectations of surgical treatment were 
in agreement with the modest long-term outcomes reported in literature. Most 
variation was observed regarding surgeons’ preferences for surgical and non-
surgical treatments of symptomatic LSS and indications for concomitant fusion 
procedures. To minimize variety, national and international protocols based on 
high-quality randomized controlled trials and systematic reviews are necessary to 
give surgeons more tools to support everyday decision-making.
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Background: Despite an increasing implantation rate of interspinous process 
distraction devices (IPD) devices in the treatment of intermittent neurogenic 
claudication (INC), definitive evidence on the clinical effectiveness of implants 
is lacking. The main objective of this review was to perform a meta-analysis of 
all systematic reviews, randomized clinical trials and prospective cohort series to 
quantify the effectiveness of IPDs and to evaluate the potential side-effects. 
Methods: Data from all studies prospectively describing clinical results based on 
validated outcome scales and reporting complications of treatment of patients 
with INC with IPD placement. We searched MEDLINE, EMBASE, Web of Science, 
Cochrane (CENTRAL), CINAHL, Academic Search Premier, Science Direct up to July 
2010. Studies describing patients with INC caused by lumbar stenosis, reporting 
complication rate and reporting based on validated outcome scores, were eligible. 
Studies with only instrumented IPD results were excluded. 
Results: Eleven studies eligible studies were identified. Two independently RCTs 
and eight prospective cohorts were available. In total 563 patients were treated with 
IPDs. All studies showed improvement in validated outcome scores after six weeks 
and one year. Pooled data based on the Zurich Claudication Questionnaire of the 
RCTs were more in favor of IPD treatment compared with conservative treatment 
(pooled estimate 23.2, SD 18.5-27.8). Statistical heterogeneity after pooled data was 
low (I-squared 0.0, p=0.930). Overall complication rate was 7%. 
Conclusions: As the evidence is relatively low and the costs are high, more 
thorough (cost-) effectiveness studies should be performed before worldwide 
implementation is introduced.





Intermittent neurogenic claudication (INC) is a complex of symptoms, the most 
important being leg pain and numbness (frequently in both legs) with possibly 
associated back pain1-4. The symptoms can be diminished by flexion of the lumbar 
spine5-8. Lumbar spinal arthrosis inducing arthrosis of the facet is associated with 
INC8;9. Traditionally, bony decompression of the canal and the lateral recessus seems 
to be the golden standard in the treatment of INC3;4. There is some evidence that 
bony decompression is a proven superior therapy compared with non-surgical 
therapy, such as steroid injections or fysiotherapy10;11. Less invasive strategies 
have been developed to minimize the perioperative damage, such as unilateral 
laminotomy or endoscopic procedures12. Although surgery is frequently offered, 
detailed outcome results are not available and spine surgeons try to develop 
innovative less invasive surgical approaches to gain better outcome than the 
results observed in daily practice.
Parallel to these developments, interspinous implants for interspinous process 
distraction devices (IPD) have been developed to achieve indirect decompression13;14. 
The design of the implants aims at limitation of lumbar extension and increasing 
the interlaminar space of the affected level15-19. Nowadays, the technique is widely 
used. Kyphon Inc. had a worldwide X-STOPTM net sale, in the first quarter of 2007, 
of 18.1 million USD. Paradigm Spine Inc. reported in May 2010 a worldwide sale of 
13,128 CoflexTM devices in 200920. The existing evidence seems to be poor; almost 
no comparative studies between conventional surgical decompression and surgery 
with IPD are done17;21-24. Some claim, performing IPD placement in day surgery and 
with local anesthesia will lower the costs. However, a thorough cost-analysis has 
never been performed.
The main objective of this systematic review was to evaluate if surgery with IPD is 
more effective compared with bony decompression in the treatment of patients 
with INC or at least more effective compared with conservative (e.g. steroid 
injections) treatment.




This systematic review was performed according to the Cochrane systematic 
review methodology, up-dated by Furlan and Van Tulder and the Meta-analysis Of 
Observational Studies in Epidemiology (MOOSE) criteria25-27.
Search strategies
On July 1st 2010, a search of relevant systematic reviews on IPD in the Cochrane 
Library and, in addition, observational cohort studies (with and without control 
group), systematic reviews and randomized clinical trials was conducted in MEDLINE, 
EMBASE, Web of Science, Cochrane (CENTRAL), CINAHL, Academic Search Premier, 
Science Direct. Keywords used for the search were: interspinous implant surgery, 
interspinous implants, interspinous distraction devices, interspinous decompression 
device, interspinous process decompression, intermittent neurogenic claudication, 
neurogenic claudication, lumbar stenosis, or spinal stenosis. The full search strategy 
is available upon request from the corresponding author. References of retrieved 
articles and relevant overview articles were checked to identify additional studies.
Inclusion criteria
Prospective cohort studies, systematic reviews and/or RCTs written in English were 
considered eligible for inclusion if they fulfilled all of the following: 
1.  The study population consists of patients with INC caused by lumbar stenosis.
2.  Patients with INC without or with degenerative spondylolisthesis to a maximal 
grade I. One of the treatments consists of non-instrumented IPD for treating 
symptoms of INC (excluding pedicle screw fixations combined with IPD).
3.  A validated outcome score is used to evaluate the outcome after surgery, the 
Zurich Claudication Questionnaire or the Modified Roland Disability Questionnaire 
for Sciatica, Oswestry Disability Index, VAS leg and back pain28-34;34-39.
Studies, in which subgroups met our inclusion criteria, were included in our results 
if the results for these subpopulations were reported separately.
Study selection
Two reviewers independently applied the inclusion criteria to select potential 
relevant studies from the titles and abstracts or if necessary the complete 
publication of the references retrieved by the literature search. Where necessary, a 
third reviewer was consulted to resolve a disagreement.




Categorization of the relevant literature
Relevant literature was categorized under three different headers: systematic 
reviews, RCTs, and prospective cohort studies of high quality. The header 
‘systematic reviews’ describes all systematic reviews. The header ‘RCTs’ contains all 
published RCTs on the same intervention comparing IPD with decompression or 
conservative treatment. Additional prognostic cohort studies were included. The 
header ‘observational cohort studies’ contains all prospective cohorts with adequate 
description of the follow-up period and validated outcome measurements. When, 
due to lack of evidence, pooling data was not possible a descriptive review would 
be performed based on RCTs and prospective observational cohort studies.
Methodological quality assessment
Systemetic reviews were validated using the steps defined by Furlan and Van 
Tulder27;40. To identify potential risks of bias of the included RCTs two reviewers 
independently assessed the methodological quality of each RCT according to the 
Cochrane quality measurements adapted by Furlan and Van Tulder25;27;41;42. Each 
item was scored as “yes”, “no”, or “don’t’ know”. High quality was defined as a score 
of 50% or more on the methodological quality assessment. The Dutch Cochrane 
Centre Quality Assessment (DCCQA) scale was used for the validation process for 
observational studies. According to the Dutch Cochrane Centre Quality Assessment 
scale, a score below six was defined as low methodological quality on the DCCQA 
scale. A third reviewer could be consulted to solve disagreement between the 
reviewers.
Data extraction
Independently, data were extracted by two reviewers. Information was collected on 
the study population, intervention(s) performed, outcome measures and outcome. 
The follow-up time was categorized into short-term outcome (six weeks after 
intervention) and long-term outcome (at least one year). Furthermore, complication 
rate and device failure (a re-intervention or other surgical technique was necessary) 
were recorded. Despite the often mentioned spinal process fractures, all other 
causes for surgical re-interventions were also recorded43-46.
Outcome measurements
There are various classifications to describe neurological and functional outcome of 
patients with intermittent neurogenic claudication. Articles were filtered on presence 
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of one of the four mostly used outcome scales. Firstly, articles were included on the 
Zurich Claudication Questionnaire (ZCQ), also known as the Brigham Spinal Stenosis 
Questionnaire and Swiss Spinal Stenosis Questionnaire35;38;39. The ZCQ scale consists 
of three subscales: symptom severity, physical function and patient satisfaction. 
Domain scores ranges from 1 to 5, 1 to 4, and 1 to 4 respectively. Like in the study of 
Tuli in 2006, we chose threshold scores for each scale based on prior work35;38;39;47. In 
the symptom severity scale and in the physical function scale the minimal clinically 
important difference (MCID) is 0.538;39. A mean patient satisfaction score of less than 
2.5 has been shown previously to represent a satisfied patient38;39. Secondly, articles 
were used on the Modified Roland Disability Questionnaire for Sciatica (MRDQ). 
The 23-points MRDQ is the most widely used patient-assessed measure of health 
for low back pain and leg pain29-34;34;36. This questionnaire consists of 23 questions 
with higher scores indicating increased disability48. The Visual Analogue Scale (VAS) 
is one of the most used follow-up measurement tools for back pain and leg pain49. 
This parameter will measure the experienced back and leg pain intensity in the 
week before visiting the research nurse. Pain will be assessed on a horizontal 100 
millimeters scale varying from 0 millimeter, “no pain”, to 100 millimeters, “the worst 
pain imaginable”49. This parameter has a minimum clinically important difference 
(MCID) of 2 points on a scale of 0 to 1050. Finally, the Oswestry disability index 
(ODI), where 0 indicates no disability and 100 indicates worst possible disability, 
was included for our analysis51. This parameter has a minimum clinically important 
difference (MCID) of 10.0-12.4 points50;52;53.
Data synthesis
A meta-analysis was performed if two or more RCTs were available with clinical 
homogeneous patient groups and statistical homogeneous results. When not 
possible, due to small amount of studies or heterogeneity, a best-evidence synthesis 
was used. Best evidence synthesis was performed stratified for studies meeting 
50% or more opposed to those meeting less than 50% of the quality criteria of 
the Van Tulder list27. The study was only included in the best-evidence synthesis if 
a comparison was made between the groups (IPD placement versus conservative 
treatment or IPD placement versus surgical decompressive treatment). When meta-
analysis or best evidence synthesis based on RCT is not possible, a data extraction 
based on observational studies (with or without control group) will be performed. 
Although a high risk of bias is possible, if possible we performed a data extraction 
from observational studies based on the “best-of-the-rest” principle. 






The search revealed 253 references. 222 articles were excluded on the basis of the 
abstract, title and keywords. 20 articles were excluded after reading the complete 
articles because of the following reasons: the reports did not consist original patient 
data (4),17;23;54;55 articles were not written in English (2),56;57 there were no outcome 
results given (9),24;58-65 studies with a retrospective study design(5).43;66-69 As a result, 
only three RCTs and eight prospective cohorts were included for methodological 
quality assessment in this review (Figure 1 – Flowchart)17;21-23;70-76. 
Figure 1. Flowchart
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Description of study characteristics 
No systematic reviews could be found. Three reports of randomized clinical trials 
(RCTs) and eight prospective cohorts were found. Three reports described two 
RCTs comparing non-operative treatment to treatment with IPD; one observational 
cohort described IPD treatment versus non-operative treatment after bony 
decompression in both groups; seven cohorts described treatment with IPD only. 
Two RCTs described the results of the same patient sample. The first study published 
follow-up data after one year and the last published study after two years, both are 
shown in Table 117;23.
Methodological quality assessment
The methodological quality of the studies is summarized in Table 1 and 2. Two reports 
of one RCT (of the three RCTs) had a methodological quality score of 5 (low quality) 
and one RCT had a quality of 6 (a high quality study) according to the Furlan and Van 
Tulder criteria25;27. Only one observational study had a methodological quality of 6 
out of 8 (reflecting high quality),76 thus the remaining seven observational studies 
are of low methodological quality and with high risk of bias22;70-75.































































































































































Anderson PA no no yes no no don’t know yes yes yes yes yes 6
Zucherman JF 2004 no no yes no no don’t know yes yes yes yes
don’t 
know 5
Zucherman JF 2005 no no yes no no don’t know yes yes yes yes
don’t 
know 5





In tables 3 and 4, relevant data on the selected studies is shown with the baseline 
and postoperative follow-up scores at six weeks and 1 year. Two RCTs with different 
patients samples (the two RCTs of Zucherman were conducted on the same patient 
sample), Anderson et al. and Zucherman et al., could be used for best evidence 
synthesis17;21. Both RCTs compared conservative treatment with IPD placement 
(Figure 2 – Meta-analysis). Both studies measured follow-up data on the ZCQ. In the 
study by Zucherman et al, however, overall success rates and standard deviation 
(SD) values were not shown. A calculation was made, based on the ZCQ values of 
symptom severity and physical function ZCQ. SD values were calculated estimated 
from the SD values of Anderson et al. Both studies report 2% complication rate and 
on top of that 2% device failure (Anderson et al) and 6% device failure (Zucherman). 
Both studies measured follow-up data on the ZCQ. In the study by Zucherman et al, 
however, overall success rates and standard deviation (SD) values were not shown.
















































































































1 Bhadra AK + + + + - + - - 5
2 Brussee P + - + + - - + - 4
3 Galarza M - - + + - + - - 3
4 Kuchta J + + + + - + - - 5
5 Lee J + - + + - - + - 4
6 Richter + - + + - + - - 4
7 Siddiqui M + - + + - + - - 4
8 Yano S + + + + - + + - 6
max – maximal points available
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FU – Complete follow-up; ZCQ – Zurich Claudication Questionnaire; SS – ZCQ symptom severity domain; 
PF – ZCQ physical function domain; * Values of ZCQ overall success domain
Figure 2. Meta-analysis
IPD – interspinous process decompression; SD – standard deviation; WMD – weighted mean difference.
A calculation was made, based on the ZCQ values of symptom severity and physical 
function ZCQ. SD values were calculated estimated from the SD values of Anderson 
et al. Both studies report 2% complication rate and on top of that 2% device failure 
(Anderson et al) and 6% device failure (Zucherman). Both studies favored treatment 
with IPD placement, pooled ZCQ improvement by 23.2 (SD 18.5-27.8). Statistical 
heterogeneity after pooled data was low (I-squared 0.0, p=0.930). According to the 
statistical heterogeneity, baseline criteria in both studies showed a good clinical 
homogeneity. Richter et al. compared two surgical decompression cohorts: one 
group with surgical decompression and no IPD placement, one group with surgical 
decompression with IPD placement22. Both groups showed clinical improvement 
in the ODI, MRDQ and VAS. At six weeks and at one year follow-up there were 
no statistical significantly differences between both groups. The remaining seven 
prospective cohort studies showed improvement from baseline after treatment 




with IPD70-76. However, these groups did not compare other treatment modalities 
(such as conservative treatment) with IPD follow-up results. Due to the use of 
multiple follow-up scales, pooling of data was not possible (Table 4 – prospective 
cohort studies).
In our search of literature, 563 patients underwent implantation with IPD. 
Complication rates and device failure rates were available from 513 patients (Table 
3 – RCT and 4 – prospective cohorts). A total of 31 devices failed (6%) and had to be 
replaced or were re-operated with bony decompression and stabilization. Six (1%) 
other complications were also reported (infections and postoperative leakages).
Discussion
The literature has been systematically reviewed to evaluate the outcome for 
patients with intermittent neurogenic claudication treated with IPD versus bony 
decompression or conservative non-surgical treatment. To our knowledge, this 
is the first systematic review and meta-analysis on this subject. After a literature 
search, two independent RCTs and eight prospective cohorts, one with a control 
group, were eligible for validation and data-extraction. The methodological quality 
of the RCTs were 5 (Zucherman) and 6 (Anderson)17;21. The methodological quality 
of the remaining prospective cohort studies was relatively low (only one reached 
6 out of 8)22;70-76. In total 563 patients were treated with IPD. All studies showed 
improvement in validated outcome scores after six weeks and one year. Pooled 
data of the RCTs were more in favor of IPD treatment compared with conservative 
treatment.
The review of the literature showed that very little is known about treatment with 
IPD. Only one comparative study with good methodological quality fulfilling our 
selection criteria was found21. Different indications are used for these devices, 
such as described by Richter who used an IPD in combination with surgical 
decompression22. Some studies show beneficial effect of surgical technique 
compared to conservative treatment for patients with degenerative lumbar spinal 
stenosis and neurogenic intermittent claudication10;11. More centers, however, 
perform complex techniques rather than only a decompression technique. 
Between 2002 and 2007, complex fusion procedures showed a 15-fold increase in 
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the USA. Furthermore, the overall procedure rate slightly decreased with 1.4%77-79. 
Coflex worldwide implants increased from 1,717 in 2005 to 13,128 in 2009. Even 
without evidence of implantation of an IPD as a treatment strategy for INC, some 
centers use it in a combination with other techniques22. Despite the fact that no 
arguments exist in the literature about the effectiveness of treatment with IPD 
versus bony decompression, many centers throughout the world use IPD for the 
treatment of INC.
Overall complication and failure rate of (7%, including 6% reoperations rate after 
device failure) tended to be relatively low compared to the complication rate of 
standard bony decompression. For example, Weinstein and Malmivaara reported 
a complication rate of 17-24% in the standard bony decompression operation 
cohorts10;11. The most frequently reported complications in these series are dural 
tears and wrong level surgery. Due to the use of standard X-rays in the operation 
theater with IPD treatment, wrong level surgery in interspinous decompression 
surgery is rare. Most techniques of interspinous decompression are indirect and 
with some distance from the dura, therefore causing a dural tear is difficult by regular 
surgical methods. Despite the large numbers of case reports on complications 
after IPD treatment, complication rates tends to be low43;44;80;81. This, however, 
might be induced by selection bias of published studies. Despite the relatively 
low complication rate, device failure rate needing reoperation is high (6%). This 
number can be higher because of the publication bias, but also due to the lack of 
long-term follow up. 
This conclusion is difficult to confirm due to the fact that no comparative studies 
are done on this subject.  Combined with the 6% device failure rate complication 
rate, the IPD complication rate is 7%. In the literature, implantation surgery is 
associated with complication rate of 8% (2-6% failure rate)79. The complication rate 
would be possible higher when complications would be monitored thirty days 
after discharge. Not all studies included in our review reported complication rate 
thirty days after hospital stay. Prospective reporting of complication should be 
made standard in future trials. 
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The most important limitation of this review concerned the methodological 
weaknesses and selection biases of the included studies:  the vast majority 
was observational, without independent outcome assessment, and without 
complications well defined. Additionally, we combined two different RCTs for our 
meta-analysis17;21. Both studies did not mention a thorough power or sample size 
design, resulting in a 191 patients in one RCT and 75 in the other. Furthermore, 
only one study was of relatively high methodological quality. Therefore possible 
information bias could be introduced. Furthermore we excluded 242 studies, 
introducing selection bias. Due to the retrospective design of some of these 
studies, possible interesting patient data had to be excluded. Studies that were 
published in abstract or poster format only were excluded. The present study 
was aimed at identifying published peer-reviewed literature, so that influence of 
publication bias cannot be ruled out. Due to the small number of studies, possible 
publication bias (using e.g. funnel plot) could not adequately be assessed. Due to 
the anticipated low number of RCTs, prospective studies were also included. Most 
of these studies were of low methodological quality (Table 2 – Validation). Due to 
the inclusion of studies of low methodological quality, information bias is easily 
introduced. Furthermore, methodological quality assessment does not take into 
account the author’s disclosure. For example, two studies in our review stated that 
one of the authors is a consultant and, in one article, stockholder of the company 
manufacturing the IPD device they were using for their study21;70. The remaining 
studies did not mention any conflict of interest or disclosure. Seven studies did 
not even describe the possible conflicts of interest. Assessing possible conflict of 
interest is not incorporated in both validation scales25;27. Standard adjusting both 
scales based on possible conflict of interest is advisable.
This review of the literature shows that surgical decompression with interspinous 
process devices is superior to conservative non-surgical treatment in patients with 
lumbar degenerative spinal stenosis with INC. However, the level of evidence for 
this conclusion is debatable due to the low quality of some of the included studies. 
Furthermore, no data is presently available comparing interspinous process 
decompression with standard bony decompression. We suggest that more studies 
will be done on this subject comparing the surgical treatment with IPD versus bony 
decompression. Despite the fact that we could give a Grade A recommendation, 
according to the Oxford-Centre for Evidence Based Medicine, we suggest that 
further studies have to be performed before a thorough recommendation can be 




given regarding the treatment of INC with IPDs80.  These studies should also include 
analysis on complication rate and device failure rate. As the evidence is relatively 
low and the costs are high, more thorough cost-effectiveness studies should be 
performed before worldwide implementation is introduced. Because the golden 
standard for surgical decompression seems to be absent, patients with lumbar 
spinal stenosis should be guarded against instrumented surgery or the use of IPD 
on the basis of the current evidence.
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Background: Decompressive laminotomy is the standard surgical procedure 
in the treatment of patients with canal stenosis related intermittent neurogenic 
claudication. New techniques, such as interspinous process implants, claim a shorter 
hospital stay, less post-operative pain and equal long-term functional outcome. A 
comparative (cost-) effectiveness study has not been performed yet. This protocol 
describes the design of a randomized controlled trial (RCT) on (cost-) effectiveness 
of the use of interspinous process implants versus conventional decompression 
surgery in patients with lumbar spinal stenosis.
Methods/Design: Patients (age 40-85) presenting with intermittent neurogenic 
claudication due to lumbar spinal stenosis lasting more than 3 months refractory 
to conservative treatment, are included. Randomization into interspinous implant 
surgery versus bony decompression surgery will take place in the operating room 
after induction of anesthesia. The primary outcome measure is the functional 
assessment of the patient measured by the Zurich Claudication Questionnaire (ZCQ), 
at 8 weeks and 1 year after surgery. Other outcome parameters include perceived 
recovery, leg and back pain, incidence of re-operations, complications, quality of 
life, medical consumption, absenteeism and costs. The study is a randomized multi-
institutional trial, in which two surgical techniques are compared in a parallel group 
design. Patients and research nurses are kept blinded of the allocated treatment 
during the follow-up period of 1 year.
Discussion: Currently decompressive laminotomy is the golden standard in the 
surgical treatment of lumbar spinal stenosis. Whether surgery with interspinous 
implants is a reasonable alternative can be determined by this trial.
Dutch Trial register number: NTR1307
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Background
Intermittent Neurogenic Claudication (INC) is a complex of symptoms first described 
by Van Gelderen in 1948 and in 1950 by the Dutch neurosurgeon Verbiest, therefore 
formerly known as the Verbiest syndrome [1-4]. The characteristic symptom is 
described as leg pain (frequently in both legs) which can be exacerbated with 
prolonged walking or lumbar extension. Others, like Evans, describe a cramp, 
tightness or discomfort of the legs after walking which diminish after a short period 
of sitting or bending forward [1]. Apart from the leg pain, associated low back pain 
may occur [5].
Since the description of neurogenic claudication by Verbiest, explanation of the 
symptoms has been disputed. Verbiest stated in 1954: “In the writer’s humble opinion 
the ligamentum flavum is most unlikely to contact any spinal root unless this root is 
distorted from its regular path”[4]. Evans showed in 1964 a cerebral spinal fluid stop 
at the low lumbar levels narrowing of the canal by degenerative facet arthrosis 
resulting in nerve root compression. INC is often seen in patients with lumbar 
degenerative spinal stenosis [4]. Due to this arthrosis of the facet joints, lumbar 
nerve root compression will develop. Arnoldi described multiple types of lumbar 
spinal stenosis. His article published in 1975 was actually a summarization of a 
symposium on this subject [4,6]. Presently, his classification is still widely used. Like 
in any acquired disease, INC is usually seen in the elderly [1].
The best treatment of NIC due to lumbal stenosis remains controversial [5,7]. 
Nonoperative therapy like epidural steroid injections, nonsteroidal anti-
inflammatory medication, analgesics, physical therapy, and spinal manipulation, 
is frequently performed [8]. A 2005 Cochrane review found that the paucity and 
heterogeneity of evidence limited conclusions regarding surgical efficacy for spinal 
stenosis [7,9-12]. Indeed, Weinstein et al published in his article the results of a 
randomized cohort study with relatively poor results in the non-operative group 
[13-15]. Despite the high level of crossovers in their study, the treatment effect was 
favouring surgery on the SF-36 scale for bodily pain. Also Malmivaara et al showed 
a better recovery after surgery versus conservative treatment with a difference 
of improvement of 11.3 on the ODI disability scale [16]. Furthermore Turner et al 
published in their attempted meta-analysis a success rate (good to fair outcome) 
of 64% after surgical bony decompression in patients with INC [17].
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Thomé et al prospectively compared the most typically used techniques: 
laminectomy, unilateral laminotomy and bilateral laminotomy [18]. In the series 
of Thomé et al, bilateral laminotomy achieved an 80% success rate. It was slightly 
better compared to laminectomy, which had 70% success rate [18]. Many authors 
claim that bony decompressive surgery might facilitate spinal fusion in the 
future [19,20]. Furthermore, local trauma in these surgical strategies should not 
be underestimated [21]. The above described operations are usually performed 
under general or local anaesthesia and 2 to 7 days hospitalization maybe required, 
followed by an 8-weeks recovery period. Furthermore, the clinical outcome seems 
disappointing, since 35% of the patients documented bad outcome [13-17].
Minimally invasive surgery has gained popularity in recent years, resulting in the 
development of interspinous implants in the 1980s [22]. One of these models, the 
Wallis device, was made with a band around the spinous processes. Later in 2003 
X-stop, in 2005 Diam, in 2006 Coflex, and afterwards various other kinds of forms were 
developed to stabilize or distract the interspinous distance [23-33]. These implants 
are all placed between spinous processes, which will lead to distraction of the 
interspace with consequent indirect decompression of the nerve roots. Presently, most 
publications refer to X-stop implants [8,23-26,29-31,34-36]. It is claimed that this indirect 
decompression will reduce the pressure on the nerves leading to a return to a neutral 
or slightly tightened position of the vertebral column. Nevertheless, this is a far smaller 
operation and gives perhaps less destruction to the bony elements of the vertebral 
column. Therefore, IPD is believed to have better short-term recovery and similar long-
term (cost-) effectiveness [8,34,36,37]. Outcomes were reported to be quite favourable 
in selected series of poor methodological quality. The first randomized multicentre 
study on interspinous devices compared X-stop with non-surgical treatment [36]. 
After 2 years, the IPD group shows both clinically and statistically significant improved 
results in comparison with the conservative treated group [8,36]. However, this trial 
only compared IPD with conservative treatment. Good evidence on IPD versus other 
surgical treatment is not yet available. Verhoof et al reported in 2008 a high failure rate 
in IPD (X-stop), with an average slip on the radiographs of 19.6%, and a high surgical 
re-intervention rate (seven out of the 12) [35].  Strömqvist reported 13 re-operations in 
a group of 50 patients [38]. Park et al published one of the few studies with the Coflex 
implant [39]. However they only placed a Coflex implant after bony decompression 
[40]. Furthermore long term results, despite from the small retrospective series (twenty 
patients) of Kondrashov et al, are not yet available [34].  
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The golden standard in surgical treatment for lumbar spinal stenosis is bony 
decompression to which all new techniques should be compared. The purpose of our 
study is to asses whether IPD-surgery is more (cost) effective compared with surgical 
decompression in patients with INC due to lumbar stenosis. It is hypothesized that IPD 
gives particularly a favourable short term effect, necessitating a short term evaluation.
Methods/design
An observer and patient blinded randomized (cost-)effectiveness trial in the 
treatment of lumbar spinal stenosis is presented. In this trial two surgical techniques 
are compared in a parallel group design. The primary outcome measurement is the 
Zurich Claudication Questionnaire. The follow-up period will last 1 year. In order to 
collect enough patients, a multi-center design is necessary. The study protocol was 
approved in all participating hospitals (see table 1: list of hospitals).
Our primary question is whether IPD-surgery is more (cost-)effective compared 
with surgical decompression after 8 weeks in people with intermittent neurogenic 
claudication due to lumbar stenosis. The main advantage of IPD might be a faster 
recovery after surgery, but after long term follow-up it is unknown if this treatment 
effect will remain. Therefore, in addition, long-term follow-up (one year) will be 
compared with short-term follow-up.
Table 1. list of hospitals participating in the Felix Trial
- Leiden University Medical Centre
- Medical Centre Spaarne, Hoofddorp
- Medical Centre Rijnland, Leiderdorp
- Medical Centre Diaconessenhuis, Leiden
- Medical Centre Haaglanden, The Hague
- Medical Centre Bronovo, The Hague
- Medical Centre Groene Hart, Gouda
- Medical Centre Reinier de Graaf, Delft
- Medical Centre Vlietland, Schiedam
- Medical Centre Canisius Wilhelmina, Nijmegen
- Medical Centre Haga, The Hague
- Medical Centre Isala, Zwolle
- Medical Centre Alkmaar
- Medical Centre Tergooier, Hilversum
- University Medical Center Utrecht




All patients between 40 and 85 years with at least three months of INC due to 
spinal canal stenosis are eligible for this study. Imaging studies (MRI) must confirm 
a narrowed lumbar spinal canal, nerve root canal or intervertebral foramen at one 
or two levels. Patients have received at least three months of conservative therapy. 
Lumbar discectomie is not possible during IPD surgery. Therefore, patients should 
be excluded when a surgical relevant herniated disc is present. Additional inclusion 
and exclusion criteria are listed in table 2. Patients are referred by a neurologist with 
MRI and conventional imaging of the lumbar spine. During the first visit to the 
neurosurgical outpatient clinic, the patient’s history and a standard neurological 
examination will be documented. Conform our selection criteria, the neurosurgeon 
decides whether a patient is eligible for the Felix (Foraminal Enlargement Lumbar 
Interspinous distraXion) trial and informs the patient about both surgical techniques.
Table 2. inclusion and exclusion criteria
Inclusion criteria:
- signed informed consent
- 40 to 85 years
- has INC, as noted by leg/buttock/groin pain with or without back pain
- at least three months conservative treatment
- has a regular indication for surgical intervention INC
- has a narrowed lumbar spinal canal, nerve root canal or intervertebral foramen at one or two levels 
confirmed by MRI
- is physically and mentally willing and able to comply with, or has caregiver why is willing and able 
to comply with, the post-operative evaluations
Exclusion criteria:
- has a cauda equina syndrome
- has a herniated  disc at the same level, necessitating lumbar discectomy
- has Paget’s disease, severe osteoporosis or metastasis to the vertebrae
- has significant scoliosis (Cobb angle >25 degrees)
- has had previous surgery of the same lumbar level
- has degenerative spondylolisthesis > grade 1 (scale 1 to 4) at the affected level
- has significant instability of the lumbar spine
- has severe co morbid conditions
- has a fused segment at the indicated level
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The study, with both treatment options, will be explained to patients and, in case 
of a positive reaction, appointments are made with research nurses. Because the 
patient needs sometime to consider participation, the first visit to the research 
nurse is planned after at least 2 days. After informed consent, the questionnaires, 
outcome measures and baseline variables are recorded.
Ethical considerations
In concordance to the declaration of Helsinki, the study has been reviewed by an 
independent ethical committee and approved as being ethically constituted. The 
design of this study is approved by the Leiden Ethical Medical Committee. Every 
participating center independently needs an approval before they may include 
patients for this trial. Freely given informed consent will be obtained from a patient 
before inclusion in this study. This means that a patient has the right to know that he 
is being asked to take part, and that he does not have to do so unless he chooses. 
The patient will also be informed that there will be no financial rewards if he or she 
agrees to participate.
Randomization procedure
Patients will be randomly allocated to either IPD or conventional decompression. 
Randomization will take place in the operating room within 4 weeks after inclusion 
by the research nurse. A randomized block design, stratified by hospital and research 
nurse, is used to ensure equal distribution of both treatments while ensuring by 
imposing a variable, random block size that the next treatment is not predictable 
for the surgeon. The randomization was prepared by the study statistician and the 
principle data manager at the department of Biostatistics. They were not involved 
in the selection and allocation of patients and prepared coded, sealed envelopes 
containing the treatment allocation. In the operating room, after induction of 
anesthesia, the surgeon will open the envelope and the allocated treatment will be 
performed. Patients, nursery department and research nurses are kept blinded for the 
allocated treatment during the follow-up period of 1 year. The operation report will 
be kept separately and will only be available in case of complications or reoperations. 
Interventions
After the induced general anesthesia, randomization in group (A) IPD and (B) 
surgical decompression will be performed. The patient is positioned in knee-
elbow position or prone, dependent by the preference of the surgeon. The affected 
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spinal level is verified fluoroscopically. The participating surgeons have experience 
in both techniques and performed at least five implant operations and 15 bony 
decompression operations. 
A) IPD 
A median lumbar incision is made over the spinous processes, the laminae of 
the affected level(s) are exposed subperiosteally, and the supraspinous ligament 
will be incised. The interspinous ligament of the affected level is removed. No 
decompression will be performed and the ligamentum flavum will remain intact. 
A CoflexTM device is placed in the created space between the spinous process with 
insertion of instrumentation. The wound will be closed in layers with a suction 
drain. The titanium CoflexTM implant that fits between the spinous processes. The 
CoflexTM is available in 5 sizes: 8mm, 10mm, 12mm, 14mm and 16mm. The size 
refers to the minor diameter of the oval spacer assembly of the CoflexTM. Patients 
will be operated with loupe magnification or microscope depending surgeon’s 
preference. When an IPD fails, a standard laminotomy will be performed.
B) Surgical decompression
Similarly as in group A, a median lumbar incision will be made and the paravertebral 
muscles will be dissected subperiosteally and retracted bilaterally. Decompression 
will be applied via partial resection of the affected laminae and no complete 
laminectomy will be performed. The lateral recess will be opened bilaterally and 
medial facetectomy will be performed in order to maintain stability of the segments. 
The wound will be closed in layers with a suction drain. Like in the IPD group, 
patients will be operated with loupe magnification or microscope depending on 
the surgeon’s preference.
The patient will be allowed to leave the bed and walk without aid on the day 
of surgery. If the patient regains his/her physical function, the patient will be 
discharged. In both studies, patients and their guided physiotherapists are 
stimulated to resume home activities and work as soon as possible. The latter are 
blinded for the allocated treatment arm as well.
Baseline data
The baseline questionnaire assesses demographics, hobbies, sports, work status, 
smoking status, low back pain history, family history of INC, co-morbidity, weight 
and length. The patient’s satisfaction at work will be registered. The patient’s and the 
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surgeon’s treatment preference for IPD or decompression surgery will be assessed 
on a 5-point scale ranging from “strong preference for IPD” to “strong preference 
for decompression surgery”.
Outcome assessment
The validated outcome parameters described below will be used in this study and 
assessed by means of questionnaires. Follow-up examinations by the research 
nurse will take place at 2, 4, 8 weeks, 3, 6, 12, 24 and 60 months after randomization 
(see table 3: flowchart). Patients will be neurologically examined (at 8 weeks, 6, 12, 
24 and 60 months) and the main questionnaires will be filled out at home with a 
request to complete and return them. The outpatient control by the neurosurgeon 
will be at 8 weeks and more often if necessary (see table 3: flowchart)
Table 3. Flowchart 
Obtained patients’ information V1 V2 V3 V4 V5 V6a V7 V8 V9 V10
In-patient x
Out-patient x x x x x x x
Demography & diagnosis x
Basic physical examination x
Neurological examination x x x x x x
Provide study information x
Obtain informed consent x
X-ray x x
Randomisation x
ZCQ x x x x x x x x x
MRDQ x x x x x x x x
Shuttle Walking Test x x x x x x x
SF-36 x x x x x x x x
McGill Pain Questionnaire x x x x x x x
VAS for legs and back x x x x x x x x x
Perceived Recovery x x x x x x
Patient Global Impression of 
change
x x x x x x
EuroQol & VAS Quality of Life x x x x x x x x x
Patient diary x x x x x x
Review MRI x
Complications x x x x x x x x
Re-operation x x x x x x
A, questionnaires will be sent per mail with request to complete and return them; V1, visit 1 - Intake; V2, Visit 2 - 
surgery; V3, Visit 3 - Follow-up 2 weeks; V4, Visit 4 - Follow-up 4 weeks; V5, Visit 5 - Follow-up 8 weeks; V6, Visit 6 
Follow-up 3 months; V7, Visit 7 – Follow-up 6 months; V8, Visit 8 - Follow-up 12 months; V9, Visit 9 - Follow-up 24 
months; V10, Visit 10 - Follow-up 60 months




The disorder-specific functional score will be the primary outcome measure 
and can be obtained by completing the ZCQ, also known as the Brigham Spinal 
Stenosis Questionnaire and Swiss Spinal Stenosis Questionnaire [41-43]. The ZCQ 
scale consists of 3 subscales: symptom severity, physical function and patient 
satisfaction. Domain scores ranges from 1 to 5, 1 to 4, and 1 to 4 respectively. Like 
in the study of Tuli in 2006, we chose threshold scores for each scale based on prior 
work [41-44]. In the symptom severity scale and in the physical function scale the 
minimal clinically important difference (MCID) is 0.5. A mean patient satisfaction 
score of less than 2.5 has been shown previously to represent a satisfied patient 
[42,43]. Despite from the subscale analysis we dichotomize “success” and “failure”. 
When the MCID threshold was achieved in at least two domains, it was described 
as an overall success [44].
Secondary outcome measurements
1) Modified Roland Disability Questionnaire for Sciatica (MRDQ)
  The 23-points MRDQ is the most widely used patient-assessed measure of health 
for low back pain and leg pain [45-52]. This questionnaire consist of 23 questions 
with higher scores indicating increased disability [53]. Patrick et al compared 
MRDQ to patients satisfactory after from a change of 5 or more, patients feel 
themselves better. From a change of 12.4 all symptoms are completely gone. 
Others used a change of 4 or more [7]. The MRDQ will be dichotomized in “good 
result” (change of 4 or more) and “poor result” (change of 4 or less) [49-51].
2) Shuttle walking test (SWT)
  In this test a distance of ten meters has to be walked by the patients in a certain 
amount of time. This interval will be shortened until the patient does not finish 
the ten meters in the prescribed time. The SWT needs to change by 76 meters 
to ensure that walking distance is changed, but large changes can occur after 
surgery, and the SWT may thus provide a useful measure on an individual basis 
[54].
3) SF-36
  The questionnaire consists of 36 items on physical and social status of the patient 
subdivided in 8 domains: physical function, physical restrictions, emotional 
restrictions, social functioning, somatic pain, general mental health, vitality, 
and general health perception. The questions are scored on a scale of 0, “worst 
health”, to 100, “ideal health” [55,56].
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4) McGill pain questionnaire
  This score distinguishes three dimensions of pain: sensoric, affective and 
evaluative dimension [57,58].
5) Visual Analogue Scale (VAS) score of back pain and leg pain
  This parameter will measure the experienced back and leg pain intensity in the 
week before visiting the research nurse. Pain will be assessed on a horizontal 
100 millimetres scale varying from 0 millimetre, “no pain”, to 100 millimetres, “the 
worst pain imaginable” [59].
6) Likert scale
  This 7-point perceived recovery scale varies from “completely recovered” to 
“worse than ever”. Like the patient global impression of change, the scale will 
be completed by the patient and research nurse. For analysis purposes this test 
will be dichotomized in “recovered” and “not recovered” [60].
7) Hospital Anxiety Depression Scale (HADS)
  This scale consists of a 7-item depression scale and a 7-anxiety scale. The score 
range from 0-21 with a high score being indicative for depression/anxiety.
Costs
To estimate utilities the EuroQol is used [61-64]. The EuroQol consists of 5 
dimensions: mobility, self-care, daily activities, pain/discomfort, and anxiety/
depression. Together with the remaining life expectation, they form QALY’s. The 
QALY is a measure for the number of years someone still may expect, corrected for 
their quality. The EuroQol will be repeated once every two weeks during the first 8 
weeks after surgery. These frequent EuroQol measurements during the first 8 weeks 
have been chosen in order to record the changes of quality of life. After this first 
period EuroQol will be recorded on regular basis during the patient’s visit to the 
research nurse (see table 3: flowchart). The patients are also instructed to record 
a diary in which, for example, work activities will be enlisted. Furthermore direct 
medical costs will be estimated on basis of the cost centre method.
Complications and re-operation incidence
The research nurse and the neurosurgeon will record complications accurately. This 
may include infections, post-surgical haematoma, cerebrospinal fluid leakage, an 
increase in neurological deficit due to surgery, venous thrombosis and other side 
effects.




The sample size calculation is based on the hypothesis that the short-term results 
obtained after IPD are superior to the results obtained after surgical decompression. 
The ZCQ at eight weeks will be used as a primary result measure both to answer 
the first research question and to calculate the sample size. The sample size of the 
trial is based on a superiority design and calculated under the alternative null-
hypothesis to reach sufficient power to enable a distinction between the two arms 
in terms of success according to ZCQ if (according to the literature) results obtained 
after surgical decompression will be 64% and the results obtained after IPD will 
be at least 84% (20% difference in favour of IPD). A sample size of 98 patients per 
group ensures 90% power to confirm the null hypothesis when IPD is more than 
20% superior to decompression, using a likelihood ratio test in a logistic regression 
framework (see figure 1: sample size). Accounting for about 10% loss to follow-up, 
this trial will enrol 216 patients with INC (108 patients in both groups). A sample 
size of 80 patients per group (including 10% loss to follow-up) will ensure a power 
of 80%. The feasibility of reaching 216 patients available for analysis will be checked 
after reaching 160 evaluable patients without deblinding or even analysing the 
data as a group comparison. This constitutes a methodological valid approach 
since no multiple testing is involved and stopping further accrual is not based on 
an intermediate effect estimate. Since the power is based on a dichotomization of 
the underlying ZCQ scale, an alternative primary analysis of the ZCQ itself will also 
have sufficient power. The latter analysis will also take the repeated measurements 
structure into account. 
Statistical analysis
Baseline comparability will be assessed by descriptive statistics to determine 
whether randomization was successful. Differences in outcome between both 
groups, together with 95% confidence intervals, will be calculated.
Besides a difference in recovery between the two groups at two specified time 
points (eight weeks and one year), analysis of a difference in time to recovery 
will be carried out as well, using a survival analysis framework (COX hazards). All 
data are analysed according to the “intention-to-treat-principle”. Furthermore a 
repeated measurements analysis of variance will be performed on the underlying 
continuous scales. In all analyses the first assessment of treatment effect will be 
the estimate of the main effect within the appropriate model, adjusted for the 
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stratification factors and main covariates. Secondly, an interaction term evaluating 
a possible effect modification of the treatment effect by the major covariates (see 
table 5: covariates for sub analysis) is pre-specified as being part of proper statistical 
modelling of the primary treatment effect. In the presence of severe interaction, the 
treatment effect will be presented as a function of the effect modifiers. In addition, 
an explorative subgroup analysis is conducted to investigate whether treatment 
effect varies over specific subgroups of patients (table 6: subgroups). Data will be 
stored via the internet-based secure data management system ProMISe of the 
department of Medical Statistics and Bioinformatics. The analyses will be carried 
out using appropriate statistical software (e.g. SPSS, version 17).
Figure 1. Sample Size
Sample size per group vs Difference by Power 

























N1: number of patients needed in the IPD group, P1: the chosen success rate of the IPD group; P2: the suc-
cess rate of the decompression group (0.64); N2: number of patients needed in the decompression group 
(equal to N1); A: the alfa is two sided 0.05.
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Table 6. subgroups based on the following variables
Demographics
- age < 70 years versus > 70 years
- women versus men
Anamnestic and neurological variables
- short versus long history of back pain
- more leg pain versus more back pain
Radiological variables
- soft versus bony stenosis
- extent of stenosis during MRI examination
Table 5. Covariates for sub analysis
- Age and age banding (< 60 years, > 60 years or similar linked to groups size after recruitment))
- Long medical history of back pain
- Leg pain intensity
- Proportion leg pain/back pain
- Extent of stenosis during MRI examination
- Kind of stenosis (soft or bony)
- Sexe
- Surface area of spinal canal
Discussion
In this article a design of a RCT is presented which evaluates the (cost-) effectiveness 
of IPD versus decompression surgery in the treatment of intermittent neurogenic 
claudication. This is the first randomized prospective trial comparing these two 
surgical techniques. Like the Sciatica-MED trial, the research nurse and the patient 
are blinded for the allocated treatment [7]. The objective of this trial is to determine 
whether the IPD is more (cost-) effective after eight weeks compared to the 
conventional decompression surgery. 
Abbreviations
CRF, case record form; INC, intermittent neurogenic claudication; IPD, interspinous 
process device; MCID, minimal clinically important difference; MRDQ, modified 
Roland disability questionnaire; MRI, magnetic resonance imaging; QALY, Quality 
adjusted live years; RCT, Randomized Controlled Trial; SF-36, short form-36; 
SWT, Shuttle walking test; VAS: visual analogue scale; ZCQ:  Zurich claudication 
questionnaire.
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Objective: To assess whether interspinous process device implantation is more 
effective in the short term than conventional surgical decompression for patients 
with intermittent neurogenic claudication due to lumbar spinal stenosis.
Design: Randomized controlled trial.
Setting: Five neurosurgical centers (including one academic and four secondary 
level care centers) in the Netherlands.
Participants: 203 participants were referred to the Leiden-The Hague Spine 
Prognostic Study Group between October 2008 and September 2011; 159 
participants with intermittent neurogenic claudication due to lumbar spinal 
stenosis at one or two levels with an indication for surgery were randomized.
Interventions: 80 participants received an interspinous process device and 79 
participants underwent spinal bony decompression.
Main outcome measures: The primary outcome at short term (eight weeks) and 
long term (one year) follow-up was the Zurich Claudication Questionnaire score. 
Repeated measurements were made to compare outcomes over time.
Results: At eight weeks, the success rate according to the Zurich Claudication 
Questionnaire for the interspinous process device group (63%, 95% confidence 
interval 51% to 73%) was not superior to that for standard bony decompression 
(72%, 60% to 81%). No differences in disability (Zurich Claudication Questionnaire; 
P=0.44) or other outcomes were observed between groups during the first year. 
The repeat surgery rate in the interspinous implant group was substantially higher 
(n=21; 29%) than that in the conventional group (n=6; 8%) in the early post-surgical 
period (P<0.001).
Conclusions: This double blinded study could not confirm the hypothesized 
short term advantage of interspinous process device over conventional “simple” 
decompression and even showed a fairly high reoperation rate after interspinous 
process device implantation.
Trial registration Dutch Trial Register: NTR1307.
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Introduction
Recent developments in spinal surgery implants promise less invasive procedures 
with superior effectiveness to conventional surgery.[1] [2] Particularly in (older) 
patients with spinal stenosis due to arthrosis of the facet joints, implantation of an 
interspinous process device is regularly offered. However, the growing incidence 
of low back surgery with additional implants for degenerative spine disease has 
raised questions from the scientific community.[3] [4] Furthermore, the economic 
burden of management of lumbar spine disorders (lumbar spinal disorder and 
lumbar disc disease combined) was already worrisome in the 1990s, when they 
ranked fifth on the basis of cost of hospital care.[5] The increasing use of implants, 
combined with a growing older population, leads to societal concerns as the cost 
of the management of spinal stenosis is escalating.[6] [7]
Lumbar degenerative spinal stenosis is caused by arthrosis of the facet joints and 
development stenosis, which can result in lumbar nerve root compression.[8] As 
in other acquired diseases, intermittent neurogenic claudication is usually seen in 
older people.[9] Severe stenosis is common in older people’s spines: 30.4% of the 
Japanese population had a severe stenosis (average age 67.3 (range 40-93) years).
[10] Why only 17.5% of these patients have typical symptoms is not yet known. 
Most of these patients complain of a complex of symptoms, described as leg pain 
(frequently in both legs), which is exacerbated by walking, prolonged standing, or 
lumbar extension.[8] [9] [11] [12] Classically, the cramp, tightness, pain, or discomfort 
in the legs will diminish after a short period of sitting or bending forward.[9] Apart 
from the leg pain, associated low back pain may occur.[13] The optimum treatment 
of lumbar spinal stenosis is generally considered to be surgical intervention, as two 
randomized clinical trials comparing conservative treatment with conventional 
bony decompression resulted in treatment effects in favor of surgery.[14] [15] The 
treatment outcome falls short of surgeons’ expectations, as surgical decompression 
yields a modest outcome, being favorable in only 65% of patients.[14-18] This 
slightly disappointing success rate is said to be due to the destructive nature of 
bony decompressive surgery of the spinal column.[19] [20] Instability of the lumbar 
spine follows laminectomy, requiring subsequent instrumental spondylodesis.[21] 
[22] Spinal surgeons and the medical device industry are therefore looking for a less 
detrimental alternative in the surgical care for the older population.
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Minimally invasive surgery has gained popularity in recent years, resulting in the 
development of various interspinous process devices.[23] The interspinous process 
device was developed to stabilize and increase the interspinous distance with indirect 
decompression of the dural sac and nerve roots.[24-34] Treatment of neurogenic 
claudication with has been shown to be superior to conservative care.[35-37] The 
Coflex implant (Paradigm Spine, USA) was developed as a second generation 
interspinous process device to give indirect decompression and even with the 
possibility to stabilize the lumbar spine after bony decompression. Although some 
medical societies in Western countries believe in additional pedicle screw fixation 
of the lumbar spine, the scientific gold standard of surgical treatment of lumbar 
spinal stenosis is bony decompression.[38] [39] All new surgical techniques to treat 
lumbar spinal stenosis should be compared with this technique.[14] [15] [17] [40] 
Although society might be subjected to media driven medicine and early adoption 
of surgical implants, the spinal scientific community believes that well designed 
comparative studies should be conducted before a new implant can replace the 
gold standard. Interspinous process devices have been suggested to have better 
short term (eight weeks) recovery than and similar long term (cost) effectiveness 
to bony decompression.[24-27] [30-32] [34] [36] [37] [41] [42] The purpose of this 
study was to assess whether interspinous process device implantation is more 
effective in the short term than conventional surgical decompression for patients 
with intermittent neurogenic claudication due to lumbar spinal stenosis.
Methods
We did a prospective, randomized, double blind, multicenter trial among patients 
with intermittent neurogenic claudication due to lumbar spinal stenosis after failed 
conservative treatment (Foraminal Enlargement Lumbar Interspinosus distraXion: 
FELIX trial). We compared minimally invasive treatment with interspinous process 
devices against usual care (conventional bony decompression). The design and 
study protocol have been published previously.[43]
Eligibility and randomization
Patients aged between 40 and 85 years with at least three months of intermittent 
neurogenic claudication due to single or two level degenerative lumbar canal 
stenosis and an indication for surgery were eligible. All patients were diagnosed 
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as having intermittent neurogenic claudication by a neurologist in one of the 
participating hospitals. If magnetic resonance imaging showed a lumbar spinal 
canal stenosis, the consulting neurosurgeon could include patients as surgical 
candidates for the study. At the time of enrollment, an independent research 
nurse verified the persistence of the symptoms. We excluded patients with a cauda 
equina syndrome, a herniated disc needing discectomy, history of lumbar surgery, 
or significant scoliosis (Cobb angle >25°) or other spinal deformities.
We used a randomized design with variable block sizes, with allocations stratified 
according to center. Allocations were stored in prepared opaque, coded, and 
sealed envelopes. The key was accessible only to the ProMISe data management 
system of the Department of Medical Statistics and BioInformatics of the Leiden 
University Medical Center. All patients gave informed consent. After induction of 
anesthesia, the prepared envelope was opened and the patient allocated to one 
of the treatment arms. Patients, nurses on the hospital-wards, and research nurses 
remained blind to the allocated treatment during the follow-up period of one year. 
The surgical report was kept separately from the patient’s regular clinical forms and 
was available to the neurosurgeon only in case of complications or reoperations.
Interventions
Patients allocated to the experimental group were operated on under general 
anesthesia in the knee-elbow position; no bony decompression was done, and an 
interspinous process device was implanted by a posterior midline approach using 
radiographic data for localization of the appropriate level. Patients in the standard 
bony decompression group had surgery in the same knee-elbow position done 
using a similar incision length to the interspinous process device group to keep 
all caregivers blind to the allocated treatment. A partial resection of the adjacent 
laminas was executed, followed by a flavectomy with bilateral opening of the lateral 
recess. If judged necessary, a medial facetectomy was done. Patients in both groups 
received the same standard postoperative care. Patients and the research nurses 
who were following them were asked after every visit if they were still blind to the 
allocated treatment.[43]
Outcomes
The primary outcome measure was a disorder specific functional score, obtained 
by the Zurich Claudication Questionnaire.[44-46] The primary outcome score 
was assessed at baseline and at 2, 4, 8, 12, 26, and 52 weeks after surgery. The 
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questionnaire consists of three domains (symptom severity, physical function, 
and patients’ satisfaction), in which respectively seven, five, and six questions are 
answered on a five point (symptom severity) or a four point (physical function 
and patients’ satisfaction) scale. The subscale scores were the averages of the 
points obtained for every question of the subscale, with a maximum score of 5 for 
symptom severity and 4 for physical function and patients’ satisfaction. The score 
increases with increasing disability. Blinded research nurses obtained the average 
subscale scores at every follow-up visit.[43] We considered the overall Zurich 
Claudication Questionnaire score to represent a “successful recovery” when at least 
two domain subscales were judged as “success.”[47] We defined “success” on the 
symptom severity scale and on the physical function scale as a decrease of at least 
0.5 points; a score of less than 2.5 on the patients’ satisfaction subscale represented 
“success.”[45] [46]
Secondary outcome measures were the modified Roland Disability Questionnaire 
for sciatica (scores range from 0 to 23, with higher scores indicating worse 
functional status),[48-56] a 100 mm visual analogue scale for back and leg pain 
(with 0 representing no pain and 100 the worst pain ever experienced),[57] the 
Medical Outcomes Study 36 item Short Form Generated Health Survey (SF-
36) scale (based on eight scaled scores, which are the weighted sums in their 
sections),[58] [59] the McGill Pain Questionnaire (with 0 representing minimum 
pain score and 78 maximum pain score),[60] [61] and a seven point Likert-type self-
rating scale of global perceived recovery as assessed by the question of whether 
the patient had experienced recovery (dichotomized into 1-2 for recovery and 3-7 
for no recovery).[62] Furthermore, patients underwent a shuttle walking test with 
a predefined maximum distance and timeframe (1200 m or 15 min).[63] Patients 
were scored as “success” when they walked 1200 m within 15 minutes or showed 
an increase of more than 80 m compared with their baseline walking distance.[43] 
[62] [64] [65] Finally, we used a Hospital Anxiety and Depression Scale consisting of 
a seven item depression scale and a seven item anxiety scale (4 point scale from 0 
to 3).[66] The seven items of the depression scale are related (if more than 8 points) 
to depression, and the seven items of the anxiety scale are related (if more than 8 
points) to generalized anxiety disorder.[67] Most studies report a cut-off point at 8 
points. We assessed secondary outcome scores at baseline and at two (only visual 
analogue scale back and leg pain), eight 12, 26, and 52 weeks. The Hospital Anxiety 
and Depression Scale anxiety and depression scores were obtained at baseline and 
after 52 weeks.
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Sample size
The aim of this study was to assess whether the experimental surgical technique 
with an interspinous process device would be superior to conventional surgery 
for patients with intermittent neurogenic claudication due to lumbar spinal 
stenosis on short term outcome scales. Based on our main outcome score (Zurich 
Claudication Questionnaire) and an assumed minimal clinically important change 
of 20% difference in the overall success rate between the two groups at eight weeks 
and 10% loss to follow-up, we calculated that a sample size of 80 patients in each 
treatment group would be required to provide a statistical power of 0.80 and a two 
sided α of 0.05.[44-47] We determined this 20% success rate on the basis of the 
assumption that superiority would be convincing enough to change the surgical 
guidelines. Researchers had access to the data only after the full follow-up period 
of one year.
Statistical analysis
We compared groups on the basis of an intention to treat analysis. We analyzed 
differences between groups at all the follow-up (2, 4, 8, 12, 26, and 52 weeks) time 
points with repeated measurement analysis. To account for the correlation between 
repeated measurements of the same person, we used generalized estimating 
equations. We present the difference between the results for the two groups as 
an odds ratio for binary outcome variables and as mean differences for continuous 
outcome variables.[43] To investigate potential bias due to loss to follow-up, we 
did a sensitivity analysis for the primary outcome by assigning a poor outcome to 
all missing cases.
At randomization, the administrative center stratified the study for the purpose 
of analyzing possible heterogeneity among centers and attempting a clinical 
interpretation of such heterogeneity. We tested heterogeneity between centers 
by using center as a covariate in the mixed model. We combined those centers that 
were referring patients to the same hospital and the same surgeon for treatment. 
Hence, for the analysis of heterogeneity, a center means the actual location 
where the treatment (according to random allocation) took place. We used the 
ProMISe data management system of the Department of Medical Statistics and 
BioInformatics of the Leiden University Medical Center Data for collection of data 
and checking for quality. We used IBM SPSS software, version 20.0, for all statistical 
analysis.




Between October 2008 and September 2011, 203 patients with intermittent 
neurogenic claudication due to spinal stenosis were referred to the Leiden-The 
Hague Spine Prognostic Study Group. For all patients, the including neurosurgeon 
confirmed a single or two level, magnetic resonance imaging confirmed, 
degenerative stenosis and intermittent neurogenic claudication according to the 
referring neurologists. One hundred and sixty two patients gave informed consent 
and were enrolled in the FELIX trial (fig 1[f1]). One patient died while waiting for 
the operation. Two patients were found to have a severe spondylolysis of the 
L5-S1 segment at the final preoperative check-up and were excluded from the 
study, because this could cause a detrimental effect in the implant group. The 
remaining patients were randomly assigned to interspinous process device or 
decompression, and 159 patients received the allocated treatment. All patients had 
had intermittent neurogenic claudication for an average period of 23 (intermittent 
neurogenic claudication group) and 22 (decompression group) months. No 
significant differences were noted in baseline characteristics between patients in 
the two treatment arms (table 1[t1]). Seven patients were lost to follow-up in the 
interspinous process device group and one patient in the bony decompression 
group.
Successful recovery according to the Zurich Claudication Questionnaire at 
short term follow-up (eight weeks) was achieved by 63% of the patients in the 
interspinous process device group compared with 72% in the bony decompression 
group (odds ratio 0.73; P=0.44). Long term (one year) successful recovery according 
to the Zurich Claudication Questionnaire was similar in the two groups, resulting 
in 66% good results in the interspinous process device group and 69% in the bony 
decompression group (odds ratio 0.90; P= 0.77). Overall, the Zurich Claudication 
Questionnaire analysis showed no differences between the two treatment arms 
(table 2[t2]; fig 2[f2]).
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Table 1. Characteristics of patients at baseline. 
Characteristic IPD group (n=80) Decompression group 
(n=79)
Median (range) age (years) 66 (45-83) 64 (47-83)
Male sex 49 (61) 37 (47)
Median (range) duration of intermittent neurogenic 
claudication (months)
12 (2-120) 22 (1-204)
Median (range) body mass index* 27 (20-48) 28 (20-37)
Duration of back pain (categorized) 1-3 years 1-3 years
IPD patient’s preferred treatment† 39 (49) 36 (46)
Bony decompression patient’s preferred treatment† 0 (0) 3 (4)
No preference for specific treatment† 41 (51) 40 (50)
Mild paresis or sensory loss 54 (67) 56 (71)
Localization of stenosis:
  L2-L3 2 (3) 3 (4)
  L3-L4 25 (31) 22 (28)
  L4-L5 53 (66) 54 (68)
Operated at two levels: 21 (26) 16 (20)
  L2-L3-L4 2 (3) 3 (4)
  L2-L3 and L4-L5 1 (1) 0 (0)
  L3-L4-L5 17 (21) 13 (16)
Zurich Claudication Questionnaire‡:
 Mean (SD) subscale symptom severity 0-5 scale‡ 3.1 (0.5) 3.2 (0.5)
 Mean (SD) subscale physical function 0-4 scale‡ 2.6 (0.5) 2.6 (0.5)
Mean (SD) Roland Disability Questionnaire 23 points 13.0 (5.2) 14.4 (4.5)
Mean (SD) VAS leg pain (mm)§ 52 (24) 58 (24)
Mean (SD) VAS back pain (mm)§ 60 (44) 49 (25)
Median (range) SWT (m)¶ 180 (20-1260) (n=70) 140 (10-1220) (n=70)
Completed SWT¶ 8 (10) 13 (16)
IPD=interspinous process device; SWT=shuttle walking distance; VAS=visual analogue scale.*Weight in kilograms 
divided by square of height in meters. †Patients were asked if they had any treatment preference (no preference, 
IPD, or bony decompression). ‡Disease specific outcome score; at baseline, score was reported in two subdo-
mains—symptom severity (range 0-5) and physical function (range 0-4). §Intensity of pain was measured by hor-
izontal 100 mm VAS, with 0 representing no pain and 100 worst pain ever. ¶Obtained before operation; patients 
were asked to walk until they got symptoms; test was scored “complete” when patients walked 1200 m in 15 min 
without stopping.
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Figure 1. Flow chart of enrollment and follow-up
 
228 assessed for eligibility 
159 randomized 
69 excluded 
 Not meeting inclusion criteria (n=25) 
 - cauda equina syndrome or big herniated disc 
 - Paget's disease or osteoporosis or metastasis 
 - significant scoliosis (Cobb angle >25) 
 - previous surgery of the same lumbar level 
 - degenerative spondylolisthesis > grade 1 
 - severe co morbid conditions 
 Declined to participate (n=17) 
 Refused due to preference for  
 Bony decompression (n=10) 
 Refused due to preference for IPD (n=16) 
 Died during preoperative period (n=1) 
80 allocated to IPD group 
80 received allocated intervention 
7 lost to follow-up after one year 
74 analyzed after 8 weeks (6 lost to follow-up)
73 analyzed after 52 weeks (7 lost to follow-up)
79 allocated to bony decompression group  
79 received allocated intervention 
1 lost to follow-up after one year 
78 analyzed after 8 weeks (1 lost to follow-up
and 1 not attend but returned later)  
78 analyzed after 52 weeks (1 lost to follow-up)
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Figure 2. Scores on Zurich Claudication Questionnaire, modified Roland Disability Questionnaire, and visual 
analogue scale in two groups during follow-up.
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Table 3. Secondary outcomes at 8 and 52 weeks*
Outcome IPD Decompression Odds ratio† 
(P value)
% success (95% CI) on shuttle walking test: 57 (0.45 to 0.68) 59 (0.47 to 0.88)
  8 weeks (increase of 80 m or complete)  (n=73)  (n=72) 0.75 (0.33)
 52 weeks (increase of 80 m or complete) 57 (0.43 to 0.69) 
(n=66)
51 (0.40 to 0.62) 
(n=70)
1.25 (0.54)
Mean (95% CI) SF-36 score:
 Bodily pain 8 weeks 66 (61 to 71) 63 (58 to 68) (0.40)‡
 Bodily pain 52 weeks 66 (60 to 72) 62 (57 to 68)
 Physical functioning 8 weeks 64 (59 to 70) 67 (62 to 72) (0.72)‡
 Physical functioning 52 weeks 63 (58 to 69) 62 (56 to 68)
 Social functioning 8 weeks 74 (69 to 80) 76 (70 to 82) (0.95)‡
 Social functioning 52 weeks 77 (70 to 83) 77 (72 to 82)
 Physical role 8 weeks 44 (34 to 54) 42 (33 to 51) (0.96)‡
 Physical role 52 weeks 55 (45 to 65) 55 (46 to 65)
 Emotional role 8 weeks 74 (65 to 83) 80 (72 to 88) (0.46)‡
 Emotional role 52 weeks 74 (65 to 83) 79 (71 to 87)
 Mental health index 8 weeks 77 (73 to 81) 76 (72 to 80) (0.92)‡
 Mental health index 52 weeks 75 (70 to 80) 75 (71 to 79)
 Vitality 8 weeks 64 (60 to 68) 62 (58 to 67) (0.60)‡
 Vitality 52 weeks 61 (56 to 66) 59 (55 to 64)
 General health perception 8 weeks 67 (63 to 71) 63 (59 to 67) (0.34)‡
 General health perception 52 weeks 62 (57 to 67) 59 (55 to 63)
Mean (95% CI) McGill Pain Questionnaire:
 8 weeks 11 (9 to 12) 10 (8 to 12)
 52 weeks 11 (9 to 13) 10 (9 to 12) (0.70)‡
Median (range) HADS depression score§:
 Baseline 4 (0-9) 3 (1-9)
 52 weeks 3 (0-9) 3 (0-9)
Median (range) HADS anxiety score§:
 Baseline 7 (2-14) 6 (2-12)
 52 weeks 6 (1-12) 6 (0-14)
No (%) reoperations 21 (29) 6 (8%) (<0.001)§
No (%) ZCQ success of reoperated patients 10 (48) 3 (50)
No (%) operated at two levels 21 (26) 16 (18)
No of reoperations in patients operated at 2 levels 8 1 (0.03)§
% (95% CI) ZCQ success at 8 weeks 67 (45 to 83) 48 (24 to 73) 2.50 (0.06)
% (95% CI) ZCQ success at 52 weeks 49 (29 to 69) 53 (25 to 79) 0.83 (0.83)
Mean (95% CI) duration of operation (min) 24 (22 to 26) 43 (39 to 47) (<0.001)
Blood loss (mL)—categorized¶ 10-50 50-100 (<0.001)
Complications during hospital stay 5 6
 Spinous process fractures 3 ** **
Mean (SD) hospital stay 1.83 (0.9) 1.89 (1.2) (0.753)
No (%) blinded to allocated treatment XX (67) XX (86)
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HADS=Hospital Anxiety and Depression Scale; IPD=interspinous process device; ZCQ=Zurich Claudication 
Questionnaire. *Outcomes were analyzed with generalized estimating equations (GEE). †Odds ratio for bet-
ter success rate when treated with IPD versus bony decompression, based on GEE. ‡Overall P value (based 
on GEE) of interaction between two groups based on continuous outcome scale (SF-36 and McGill (0-78 
points)). §Score consists of sum score of 7 item (0-3 points per item) questionnaire ranging from 0 to 21 
points; HADS-anxiety >8 is suspect for generalized anxiety disorder; HADS-depression >8 is suspect for de-
pression. ¶0-10 mL, 10-50 mL, 50-100 mL, 100-200 mL. **Spinous process fractures were not registered as 
relevant complications in bony decompression group, so no comparison (or P value). P value with Fisher’s 
exact test and Pearson χ2.
Modified Roland Disability Questionnaire values at eight weeks recovered by a 
mean score of 7.5 for patients treated with interspinous process device and by a 
mean score of 6.5 for those treated with bony decompression (P=0.28). Generalized 
estimating equations analysis showed no differences between the two treatment 
arms (table 2[t2]; fig 2[t2]). Analysis of all other subscales—visual analogue 
scale back pain (P=0.09), visual analogue scale leg pain (P=0.54), McGill Pain 
Questionnaire (P=0.70), and Likert scale for perceived recovery (P=0.37)—showed 
no differences during the complete follow-up (table 2[t2] and 3[t3]; fig 2[f2]). 
We found no statistically significant difference in walking distance in the shuttle 
walking test at eight weeks (odds ratio 0.75; P=0.33) and 52 weeks (1.25; P=0.54) 
between the two treatment groups. Generalized estimating equations analysis on 
visual analogue scale back pain and leg pain, SF-36, McGill Pain Questionnaire, 
Likert score for perceived recovery, shuttle walking test, and Hospital Anxiety and 
Depression Scale scores also showed no differences (tables 2[t2] and 3[t3]). We 
did not adjust primary outcome scores for Hospital Anxiety and Depression Scale 
depression because of the small percentage of participants with a score of 8 or 
more (indicating depression).
Surgery time (24 min) was shorter in the interspinous process device group 
than for bony decompression (43 min) (P<0.001). Blood loss was less in the 
interspinous process device group (10-50 mL) than in the bony decompression 
group (50-100 mL) (P<0.001). Five direct (during the first initial hospital stay) 
postoperative complications occurred in the interspinous process device: one 
patient with short term (48 hours) unexplained visual disturbance, one patient 
with self-limiting pseudoradicular pain in the other leg, and three patients with 
interspinous process fractures during interspinous process device placement 
(table 3[t3]). Direct postoperative complications occurred in six patients in the 
bony decompression group: two patients with direct epidural hematoma needing 
reoperation and four patients with dural tears without further consequences. Late 
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reoperation due to absence of recovery was indicated and performed in 21 (29%) 
cases in the interspinous process device group compared with 6 (8%) in the bony 
decompression group (P<0.001). Of patients who initially received an interspinous 
process device and were reoperated (explantation of the device and subsequent 
bony decompression), 48% scored successful recovery on the Zurich Claudication 
Questionnaire; of patients in the bony decompression group who were reoperated, 
50% scored successful recovery. The Zurich Claudication Questionnaire outcome 
of the patients reoperated after interspinous process device placement did not 
differ significantly from that of the other patients (P=0.08). Average hospital stay 
was similar in both groups: 1.83 days for the interspinous process device group and 
1.89 days for the bony decompression group (P=0.753). Patients were successfully 
blinded to the treatment chosen in 67% of the IPD group and 86% of the standard 
decompression group.
We did a sensitivity analysis to assess the effect of the missing values for our primary 
outcome. Firstly, we replaced all missing values with unfavorable outcomes. This 
did not affect our results in any substantial way. Next, we replaced all missing values 
with favorable outcomes. Again, we saw no substantial changes to our results. The 
results for the primary outcome were therefore not sensitive to loss to follow-up.
Thirty seven patients were operated on at two levels (tables 1[t1] and 3[t3]). The 
subgroup of patients with lumbar spinal stenosis operated on at two levels with 
an interspinous process device (21 patients) had a similar outcome on the Zurich 
Claudication Questionnaire scale at eight weeks (odds ratio 2.5; P=0.06) and at 
one year (0.83; P=0.83) to those allocated to the bony decompression group (18 
patients). Generalized estimating equations analysis showed no difference in 
Zurich Claudication Questionnaire results between one and two levels of surgery 
(P=0.44). However, the reoperation rate of 38% (eight patients) in the interspinous 
process device group at two levels was higher than the reoperation rate in the bony 
decompression group of 6% (one patient) (P <0.05).
We found no clinically significant heterogeneity in the outcomes between the five 
centers (supplementary appendix). The small difference supports the contention 
that the sample of hospitals is a good representation of the Dutch healthcare 
system.




Implantation of an interspinous process device as definite treatment for lumbar 
spinal stenosis did not show the hypothesized short term superior effect 
over standard bony decompressive surgery. The one year follow-up results of 
both surgical procedures did not differ, although the reoperation rate for the 
interspinous process device was significantly higher than that for conventional 
bony decompression. Another study started in 2007 was terminated when an 
interim analysis showed a fourfold higher reoperation rate in the interspinous 
process device group.[68] The shorter operation time was the only beneficial 
parameter for patients in the interspinous process device group compared with 
the bony decompression group, but this did not result in a shorter hospital stay. 
Furthermore, patients operated on at two levels had an even higher reoperation 
rate compared with bony decompression. The absence of short term added value 
of the interspinous process device and the much higher reoperation rate in this 
study do not allow this new procedure to replace the golden standard of simple 
bony decompression as treatment for lumbar spinal stenosis.
Strengths and limitations of study
One of the strengths of this study is that this is the first and only blinded randomized 
study on this subject. Furthermore, by anomyzation during data analysis, we 
excluded bias as much as possible. However, the study has also features that may 
limit the generalizability of its findings. Firstly, selection bias could have been 
introduced through the opinion of the including neurosurgeon that patients with 
severe spinal stenosis on magnetic resonance imaging should not be offered an 
interspinous process device and were thus not included in the FELIX trial. However, 
clinical features of the patients included in this study showed baseline values 
(mean visual analogue scale (leg and/or back) of 60 mm at baseline) comparable 
to those of other large trials.[14] [15] Trials in general tend to include standard 
patients, but, as mentioned earlier, not all patients with stenosis have clinical 
complaints, which could lead to potential bias that may limit the generalizability. 
The number of reoperations in the interspinous process device treatment arm is 
very worrisome, especially because reoperations do not reach the success rate of 
primary surgeries; use of interspinous process devices might even prevent recovery 
in 20% of patients. Lastly, shuttle walking tests are believed to be the most objective 
parameter to classify the disease specific complaints of lumbar spinal stenosis. As 
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in many other studies, however, using this test for an older population is often 
difficult.[14] Further research should focus on finding a new objective parameter 
to evaluate the increasingly older population with lumbar spinal stenosis.
Comparison with other studies
Others researchers have tested the interspinous process device as an alternative 
for posterior and intercorporal fusion in patients with lumbar spinal stenosis.[69] 
[70] In Dutch practice, instrumental spondylodesis is not a standard adjuvant in 
spinal stenosis surgery, and nor is it standard in the modern literature.[2] [36] [37] 
[41] [43] Nevertheless, two studies compared a wide laminectomy combined with 
interspinous process device placement against treatment with wide laminectomy 
combined with posterior and intercorporal fusion.[69] [70] Both studies concluded 
that adjuvant interspinous process device treatment is as effective as lumbar 
360° instrumentation in resolving neurogenic claudication. In addition, a non-
randomized study had already shown that patients with intermittent neurogenic 
claudication treated with bony decompression alone had the same long term 
satisfactory outcome as did patients treated with bony decompression and adjuvant 
interspinous process device placement.[71] [72] Furthermore, a recent smaller non-
blinded study reported similar results to those presented here. The clinical outcome 
of patients treated with an interspinous process device was not superior to that in 
patients treated with bony decompression. As in our study, patients had a higher 
rate (26% v 6%) of reoperation in the interspinous process device group.[73] All 
studies, including our trial, found no differences between groups with regard to 
postoperative visual analogue scale leg and back pain.[69] [70]
The results of this study and previous studies lead to the overall conclusion that 
intermittent neurogenic claudication treated with decompression alone results in a 
comparable outcome compared with treatment with interspinous process device 
alone, interspinous process device combined with bony decompression, and 360° 
instrumented spondylodesis. As instrumented surgery requires more from society 
and patients, the gold standard for intermittent neurogenic claudication treatment 
remains the classic bony decompression.




The hypothesized short term superior effect of treatment with interspinous 
process device over simple standard surgery was not confirmed by this double 
blind study. In contrast, treatment with interspinous process devices resulted in a 
higher reoperation rate and thus prevented a better recovery owing to the lower 
recovery rate after a second operation. As a spinal research group, we would not 
recommend the interspinous process device, considering the higher reoperation 
rate without a short term advantage and most likely with higher costs (interspinous 
process devices cost at least €2000 (£1704; $2756)). We doubt if reimbursement 
of interspinous process devices by society is appropriate. Furthermore, this study 
shows that future research in spine surgery should be very critical in the evaluation 
of a so called favorable outcome and weigh this against the disadvantages in robust 
double blind randomized trials.
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Objectives: Interspinous process devices (IPDs) are implanted to treat patients 
with intermittent neurogenic claudication (INC) based on lumbar spinal stenosis. 
Although widely implemented by the surgical community, effectiveness has not 
been compared with the gold standard bony decompression. It is hypothesized 
that patients with lumbar spinal stenosis treated with IPD have a faster short-term 
recovery, an equal outcome after two years and less back pain compared with 
bony decompression.
Design: A randomized design with variable block sizes was used, with allocations 
stratified according to center. Allocations were stored in prepared opaque, coded 
and sealed envelopes and patients and research nurses were blind throughout 
the follow-up.
Setting: 5 neurosurgical centers (including one academic and four secondary level 
care centers) included participants.
Participants: 211 participants were referred to the Leiden-The Hague Spine 
Prognostic Study Group. 159 participants with INC based on lumbar spinal stenosis 
at one or two levels with an indication for surgery were randomized into two 
groups. Patients and research nurses were blinded for the allocated treatment 
throughout the study period.
Interventions: 80 participants received an IPD and 79 participants underwent 
spinal bony decompression.
Main outcome measures: The primary outcome at long-term (two year) follow-up 
was the score for the Zurich Claudication Questionnaire. Repeated-measurement 
analyses were applied to compare outcomes over time. 
Results: At two years, the success rate according to the Zurich Claudication 
Questionnaire for the IPD group (69 % (95 % CI 57 to 78 %)) did not show a 
significant difference compared with standard bony decompression (60 % (95 % 
CI 48 to 71 %) p-value 0.2). Re-operations, because of absence of recovery, was 
indicated and performed in 23 cases (33%) of the IPD group versus 6 (8%) patients 
of the bony decompression group (p<0.01). Furthermore, long-term VAS back pain 
was significantly higher (36 mm on a 100 mm scale (95% CI 24-48)) in the IPD group 
compared to the bony decompression group (28 mm (95% CI 23-34) p-value 0.04).
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Conclusions: This double blinded study could not confirm advantage of IPD 
without bony decompression over conventional ‘simple’ decompression, two years 
after surgery. Moreover, in the IPD treatment arm, the reoperation rate was higher 
and back pain was even slightly more intense compared to the decompression 
treatment arm.
Trial registration: Dutch Trial Register Number: NTR1307




Intermittent neurogenic claudication (INC) caused by lumbar spinal stenosis (LSS) 
is common in the elderly1-3. Concomitant with progressive spinal canal narrowing 
over the years, patients start to develop the typical symptoms due to compression 
of the roots of the cauda equina: leg pain (frequently both legs) exacerbated by 
walking, prolonged standing or lumbar extension, and sometimes associated back 
pain.3-7 Surgical treatment is considered to be superior to non-surgical treatment.8;9 
Patients’ satisfaction after treatment is relatively low.8-10 This disappointing outcome 
was believed to be caused by the destructive nature of bony decompression.11-13 
Nowadays some centers even opt for combining bony decompression with 
instrumented spondylodesis (pedicle screws and/or intercorporal cages) as the 
golden standard for treatment of patients with INC caused by LSS.14-16 Many 
different new treatment options were therefore developed in the 80s and 90s, 
including less invasive procedures. In particular in (elderly) patients with LSS due 
to arthrosis of the facet joints, implantation of interspinous process device (IPD) 
is regularly offered instead of conventional bony decompression.17;18 Neurogenic 
claudicatio treatment with IPD has been demonstrated to be superior compared 
with conservative care.19-23 The IPD was developed to increase the interspinous 
distance with indirect decompression of the dural sac and nerve roots due to 
flexion of the involved segments, and to widen the entry of the spinal root canal 
at the same time.17-19;24-30 Additionally, patients are hypothetically expected to have 
less postoperative pain, a shorter hospital stay, a faster short-term recovery and less 
back pain at long-term follow-up. 
We previously published the short term 1 year results of a double-blind randomized 
trial comparing treatment with IPDs to bony decompression in patients with 
intermittent neurogenic claudication due to LSS. 31 Patients that were treated with 
an IPD without bony decompression showed similar rates of recovery at eight weeks 
and at 1 year compared to patients treated with bony decompression, although 
the repeat surgery rate in the interspinous implant group was substantially higher 
(29 %) in the early post-surgical period compared with the decompression group 
(8%; p-value <0.001). The 2-year results of the aforementioned trial are presented 
in the current paper. 
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Methods
A prospective, randomized double-blind multicenter trial was conducted among 
patients with INC based on LSS after failed conservative treatment (Foraminal 
Enlargement Lumbar Interspinosus distraXion: Felix trial). Minimal invasive therapy 
with placement of an IPD, without any attempt to decompress the spinal canal was 
compared to the usual care being conventional bony decompression. The medical 
ethics committees at the five participating hospitals approved the protocol, 
including an approval for randomization after anesthetic induction.  Written 
informed consent was obtained from all patients. The design and study protocol 
were published previously.32 Dutch Trial Register Number: NTR1307.
Eligibility and randomization
Patients between 40 and 85 years with at least three months of INC due to single 
or two level degenerative lumbar canal stenosis and an indication for surgery 
were eligible. All patients were diagnosed with INC by a neurologist in one of 
the participating hospitals. If MRI demonstrated a lumbar spinal canal stenosis, 
patients could be included as surgical candidates for the study by the consulting 
neurosurgeon. At the time of enrollment, an independent research nurse verified the 
persistence of the symptoms. Patients with a cauda equina syndrome, a herniated 
disc needing discectomy, history of lumbar surgery or those with significant scoliosis 
(Cobb angle >25 degrees) or other spinal deformities were excluded. 
A randomized design with variable block sizes was used, with allocations stratified 
according to center. Allocations were stored in prepared opaque, coded and sealed 
envelopes. The key was only accessible to the ProMISe data management system 
of the Department of Medical Statistics and BioInformatics of the Leiden University 
Medical Center. All patients gave informed consent. After induction of anesthesia 
the prepared envelope was opened and randomized allocation to one of the 
treatment arms was performed. Patients, nursery department and research nurses 
remained blind for the allocated treatment during the follow-up period of two years. 
The surgical report was kept separately from the regular clinical patient forms and 
was only available for the neurosurgeons in case of complications or reoperations.
Interventions
Patients allocated to the experimental group were operated on general anesthesia 
in knee-elbow position; no bony decompression was performed and an IPD was 
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implanted by a posterior midline approach using x-ray data for localization of the 
proper level. 
Patients in the standard bony decompression group underwent surgery in the 
same knee-elbow position using a similar incision length as the IPD group in order 
to keep all caregivers blind for the allocated treatment. A partial resection of the 
adjacent laminae was executed, followed by a flavectomy with bilateral opening 
of the lateral recess. If judged necessary, a medial facetectomy was performed. 
Patients of both groups received the same standard postoperative care. Patients 
and research nurses who were following these patients were asked after every visit 
if they were still blind for the allocated treatment.32 
Outcomes
The primary outcome measure was a disorder-specific functional score, obtained 
by the Zurich Claudication Questionnaire (ZCQ).33-35 The primary outcome score 
was assessed at baseline, direct postoperatively (2 weeks) and at 4, 8, 12, 26, 52, and 
104 weeks. The ZCQ consists of three domains (symptom severity, physical function 
and patient satisfaction) in which respectively seven, five and six questions had to 
be answered on a five point (symptom severity) or a four point (physical function 
and patient satisfaction) scale. The subscale scores were the averages of the points 
obtained for every question of the subscale, and were maximized to 5 (symptom 
severity) or 4 (physical function and patient satisfaction). The score increases with 
increasing disability. The average subscale scores were obtained at every follow-up 
moment by blinded research nurses.32 The overall ZCQ score was considered to be a 
‘successful recovery’ when two domain subscales at least were judged as ‘success’.36 
‘Success’ on the symptom severity scale and on the physical function scale was 
defined as a decrease of at least 0.5 points. A score of less than 2.5 on the patient 
satisfaction subscale was defined as ‘success’.34;35 
Secondary outcome measures were the Modified Roland Disability Questionnaire 
for sciatica (scores range from 0 to 23, with higher scores indicating worse 
functional status), 37-45   100mm visual-analogue scale (VAS) back and leg pain 
(with 0 representing no pain and 100 the worst pain ever experienced), 46 Medical 
Outcome Study 36-item short-form Generated Health Survey (SF-36) scale (based 
on eight scaled scores, which are the weighted sums in their sections),47;48 McGill 
pain questionnaire (with 0 representing minimum pain score and 78 maximum 
pain score),49;50 and a 7-point Likert self-rating scale of global perceived recovery as 
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given by the question whether the patient experienced recovery (dichotomized in 
1-2 recovery and 3-7 no recovery) compared to the baseline status.51 Furthermore, 
a Hospital Anxiety Depression Scale (HADS) consists of a 7-item depression scale 
and a 7-item anxiety scale (4 point scale from 0-3) were obtained.52 The seven items 
of the HADS-depression scale are related (if more than 8 points) to depression 
and the seven items on the HADS-anxiety scale are related (if more than 8 points) 
to generalized anxiety disorder.53 Most studies report a cut-off point at 8 points.53 
Last, patients underwent a Shuttle Walking Test (SWT) with a predefined maximum 
distance and timeframe (1200 meters or 15 minutes).54 Patients were scored “success” 
when they walked 1200 meters within 15 minutes or demonstrated an increase of 
more than 80 meters compared to baseline walking distance.32;51;55;56 Secondary 
outcome scores were assessed at baseline (VAS scores) and at 2 (only VAS back 
and leg pain), 8, 12, 26, 52 and 104 weeks. The HADS anxiety and depression were 
obtained at baseline and after 52 and 104 weeks.
Sample size 
The aim of this study was to assess whether the experimental surgical technique of 
IPD without bony decompression  would be comparable to conventional surgery 
for patients with INC due to LSS at the time point of two years after surgery. Based 
on our primary outcome score (ZCQ) and an assumed minimal clinically important 
change (MCIC) of 20% difference in the overall success rate between the two 
groups at 8 weeks and 10% loss to follow-up, it was calculated that a sample size 
of 80 per treatment group would be required to provide a statistical power of 0.80 
and a two-sided alpha of 0.05.33-36 This difference of 20% in success rate was decided 
based on the assumption that this level of superiority would be convincing enough 
to change the surgical guidelines and reimburse the costs of the IPD implant. 
Data from the 104 weeks follow-up were only accessible for the researchers after 
completion of the full 2-year follow-up period. 
Statistical Analysis 
Groups were compared based on an intention-to-treat analysis. Differences 
between groups at all follow-up (2, 4, 8, 12, 26, 52, 104 weeks) time points were 
analysed with repeated measurement analysis. To account for the correlation 
between repeated measurements of the same individual, Generalized Estimating 
Equations (GEE) were used. The difference between the results for the two groups 
were presented as an Odds Ratio (OR) for binary outcome variables and as mean 
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differences for continuous outcome variables.65 To address potential bias due to 
loss to follow-up a sensitivity analysis was performed for the primary outcome by 
assigning a poor outcome to all missing cases and a second analysis was performed 
for the primary outcome by assigning a favourable outcome to all missing cases.  
At randomization, the study was stratified by the (administrative) center for the 
purpose of analysing possible heterogeneity among centers and attempting a 
clinical interpretation of such heterogeneity. Data collection and checking for quality 
were performed with the ProMISe data management system of the Department of 
Medical Statistics and BioInformatics of the Leiden University Medical Center. IBM 
SPSS software, version 20.0, was used for all statistical analysis.
Results
Between October 2008 and September 2011 205 patients with INC due to spinal 
stenosis were referred to the participating hospitals. Patients with a single or two-
level, MRI confirmed, degenerative lumbar stenosis and INC according to their 
referring neurologists were screened for inclusion by the including neurosurgeon. 
For 162 patients signed informed consent was obtained and the patients were 
enrolled in the Felix Trial (Figure 1). One patient died during the time waiting for the 
operation. Two patients revealed a severe spondylolysis of the L5-S1 segment at final 
preoperative check-up and were excluded from the study. The remaining patients 
were randomly assigned to IPD without bony decompression or conventional 
decompression. In effect, 159 patients received the allocated treatment. All 
patients were suffering from INC for an average period of 23 (IPD group) and 22 
(decompression group) months. No significant differences were noted in baseline 
characteristics between patients in the two treatment arms (Chapter 6, table 1). 
Ten patients were lost to follow-up in the IPD group and five patients in the bony 
decompression group at two years after surgery.
Successful recovery according to ZCQ at long-term follow-up (two years) was 
achieved in 69 % of the patients in the IPD group versus 60 % of the patients in the 
bony decompression group (OR 0.65; p=0.20).  Overall, ZCQ analysis revealed no 
differences between the two treatment arms (table 2 and figure 2). MRDQ values 
at long-term (two years) decreased with 5.5 points for patients treated with IPD 
and with 6.3 points for patients treated with bony decompression (p=0.65). MRDQ 
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values at 104 weeks were equal compared with the 52 week’s value in the bony 
decompression group and slightly – not significant - higher (0.6 on a 23 point scale) 
in the IPD group. GEE analysis showed no differences between the two treatment 
arms (table 2 and figure 2). Analysis of all other subscales, VAS back pain (p= 0.26), 
VAS leg pain (p= 0.22), (p= 0.52), did not show any differences between treatments 
at all-time points during the complete follow-up (table 2&3 and figure 2).
Figure 1. Flow diagram of patients through two years of study
 
228 assessed for eligibility 
159 randomized 
69 excluded 
 Not meeting inclusion criteria (n=25) 
 - cauda equin syndrome or big herniated disc 
 - Paget's disease or osteoporosis or metastasis 
 - significant scoliosis (Cobb angle >25) 
 - previous surgery of the same lumbar level 
 - degenerative spondylolisthesis > grade 1 
 - severe co morbid conditions 
 Declined to participate (n=17) 
 Refused due to preference for  
 Bony decompression (n=10) 
 Refused due to preference for IPD (n=16) 
 Died during preoperative period (n=1) 
80 allocated to IPD group 
80 received allocated intervention 
7 lost to follow-up after one year 
73 analyzed after 52 weeks (7 lost to follow-up)
70 analyzed after 104 weeks (10 lost to follow-up)
79 allocated to bony decompression group  
79 received allocated intervention 
1 lost to follow-up after one year 
78 analyzed after 52 weeks (1 lost to follow-up)
75 analyzed after 104 weeks (4 lost to follow-up)
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Figure 2. outcome based on the ZCQ and VAS back-pain
BD bony decompression; IPD interspinous process devices
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Table 3. Secondary Outcome*
IPD decompression (p-value)
Percentage success on SWT Success - % (CI) Success - %(CI) ‡OR (p-value)
 




59 (47-0.88) 0.75 (0.33)
 




51 (40-62) 1.25 (0.54)
 




62 (50-73) 0.90 (0.76)
SF 36 Mean (95% CI.) Mean (95% CI.) (overall p-value)***
 Bodily pain 8 weeks 66 (61-71) 63 (58-68) (0.51)






 Physical functioning 8 weeks 64 (59-70) 67 (62-72) (0.35)






 Social functioning 8 weeks 74 (69-80) 76 (70-82) (0.05)






 Physical role 8 weeks 44 (34-54) 42 (33-51) (0.24)






 Emotional role 8 weeks 74 (65-83) 80 (72-88) (0.30)






 Mental health index 8 weeks 77 (73-81) 76 (72-80) (0.81)






 Vitality 8 weeks 64 (60-68) 62 (58-67) (0.36)






 General health perception 8 weeks 67 (63-71) 63 (59-67) (0.01)






McGill pain questionnaire (0-78 points) Mean (95% CI.) Mean (95% CI.) (overall p-value)***
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IPD decompression (p-value)
Operated on two levels – no. (%) 21(26%) 16(18*)
  reoperations in patients operated on two 
levels
8 1 (0.03)#
Duration of operation – minutes (95% CI) 24 (22-26) 43 (39-47) (<0.001)
Blood loss – categorized** 10-50mL 50-100mL (<0.001)
Complications during hospital stay 4 6










Blinded to allocated treatment 67% 86%
*The outcomes were analyzed with Generalized Estimating Equations (GEE). 
CI denotes confidence interval, SF-36 the Medical Outcomes Study 36-Item, and McGill pain questionnaire. 
N stands for the number of patients analyzed.
However, the back-pain in the IPD group increased in the second year after surgery 
in comparison to the one year time point (from 23 mm at 52 weeks to 36 mm VAS 
back pain at 104 weeks). In contrast, the back-pain in the bony decompression 
group remained equal (31mm at 52 weeks and  28 at 104 weeks), (p-value 0.04). 
GEE analysis on SF36 and McGill pain scores showed no differences (table 2 & 3). 
The dichotomized Likert perceived recovery scores showed 54% successful in IPD 
group and 46% successful in bony decompression group (OR 1.21, p-value 0.52). 
GEE analysis on HADS scores showed no differences. Primary outcome scores were 
not adjusted for HADS depression due to the small percentage of participants with 
an HADS depression of 8 or more (indicating depression). There was no difference 
in walking distance in the SWT at 104 weeks between the two treatment groups 
(ORs 0.90 p-values 0.76) and no difference at 104 weeks in both groups compared 
with the walking distance at 52 weeks (p-value 0.54).
Direct (post)operative complications occurred in six patients in the bony 
decompression group:  two patients with direct epidural hematoma needing 
reoperation, four patients with dural tears without further consequences. Five 
patients had complications after IPD treatment: three patients with spinous process 
fractures, and one patient was explored at the wrong level which was corrected 
during the same procedure. Re-operations, because of absence of recovery, was 
indicated and performed in 23 cases (33%) of the IPD group versus 6 (8%) patients 
of the bony decompression group (p<0.01). This is also, compared with the one year 
results (17 reoperations in the IPD group and 5 in the bony decompression group), 
Table 3. Continued
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a bigger increase in the IPD group without bony decompression in the second year 
of follow-up. Average hospital stay was similar in both groups: 1.83 days for the IPD 
group per patient (without hospital stay when operated for the second time) and 
1.89 days for the bony decompression group (p= 0.753). After reoperations patients 
were no longer blind for the type of treatment after reoperation. 
Sensitivity analysis was performed to assess the impact of the missing values in our 
primary outcome. First, all missing values were replaced by unfavourable outcomes. 
This did not affect our results in any substantial way. Next, all missing values were 
replaced by favourable outcomes. Again, there were no substantial changes to our 
results. The results concerning the primary outcome were therefore not sensitive 
to loss to follow-up. There was no clinically significant heterogeneity found in the 
outcomes between the 5 centers (supplementary appendix). The small difference 
will support that the sample of hospitals is a good representation of the Dutch 
Health Care system with high-complex patients’ centers and less-complex patients’ 
centers.
Discussion
The long-term follow-up did not show important differences in results (based 
on the ZCQ) comparing treatment with IPD without bony decompression and 
conventional bony decompression in patients with INC based on LSS. Previously 
published short-term results did not show any short-term benefit (based on 
the ZCQ) of treatment of IPD compared with bony decompression and at long 
follow-up the ZCQ rate of success was slightly higher for the IPD group, but not 
significantly.31 Furthermore, similar to the published one year analysis, the re-
operation rate was significantly higher (overall and in the period between 52 and 
104 weeks) in the IPD group compared with the bony decompression group. Back 
pain was hypothesized to be less in the group that underwent an operation with 
less tissue damage, namely the IPD without bony decompression group. However, 
this was not the result that was encountered: the long-term back pain in IPD 
group was significantly – though not clinically relevant – higher compared with 
the conventional bony decompression group. 
The recently published randomized trial comparing wide laminectomy combined 
with posterior and intercorporal fusion, to bony decompression with IPD showed 
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comparable back pain in both groups (104 week VAS back pain of 27mm and 24mm 
respectively)(Table 4).14.  In addition, it had already been demonstrated in a non-
randomized study that patients suffering from INC treated with bony decompression 
and adjuvant IPD placement (to maintain posterior dynamic stabilization) had the 
same long-term VAS back-pain as patients treated with bony decompression alone 
(Table 4).57;58 In the present study, treatment with IPD without bony decompression 
(operation with less tissue damage) did not result in less back-pain as well.
Table 4. literature comparison of VAS back-pain
Variable baseline 104 weeks
mean mm VAS (SD) mean mm VAS (SD)
Primary outcome
IPD without bony decompression
Moojen et al. 
60 (44)
n=79




















IPD with bony decompression 











N stands for number of patients analyzed.  SD stands for standard deviation from means. VAS visual-analogue 
scale. Dashes denote tests not administrated. * no precise values available in abstracts. 
The first interspinous device was designed to damp the motion of extension.17;18 A 
few years later, implants were hypothesized to achieve indirect decompression.59 
In theory, both properties should lead to less back and leg pain. Furthermore, 
devices were also designed with more rigidity to achieve a long-lasting effect.17 
In the current study, the VAS leg-pain was comparable in both groups, even after 
long-term (two years) follow-up. In both groups all success rates (MRDQ, Likert and 
ZCQ) stabilized, or even increased in the second year of follow-up, without fixation 
techniques. Indirect decompression with stand-alone device can be achieved and 
with long-lasting effect. However, the number of reoperations in the IPD treatment 
arm is worrisome. Especially because re-operated patients do not reach the success 
rate of primary surgeries, it is suggested that use of IPD prevents recovery in 20% 
of the patients.31 
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One of the strengths of this study is that this is the first blinded randomized study 
on this subject. Furthermore, due to blinding of patient information during data-
analysis, we excluded as much as possible bias. However, the present study has also 
features that may limit the generalizability of its findings. First, selection bias could 
have been introduced by the opinion of the including neurosurgeon that patients 
with severe spinal stenosis on the MRI should not be offered an IPD and were thus 
not included in the Felix Trial. However, clinical features of the patients included in 
this study demonstrated baseline values (mean VAS (leg and/or back) of 60 mm at 
baseline) comparable to those of other large trials.8;60 Another limitation might be 
the fact that, because of lack of power, a difference was not found that might exist. 
As the 2-year results do not show a significant difference, one cannot say that the 
outcomes were similar or equal. The intention of this study was to find evidence to 
present strong superiority in favour of IPD, to create arguments to reimburse the 
expensive implants. This evidence in favour of IPD, however, was not found and 
the investigators did not find any suggestion in the data that a larger sample size 
would lead to a different study result. To the contrary the higher re-operation rate 
and the higher intensity of LBP in the IPD group do suggest inferiority compared 
to classical decompression.
Conclusion
This double blinded study could not confirm advantage of IPD without body 
decompression over conventional ‘simple’ decompression. Since the introduction 
thirty years ago there is a lack of proof of the superiority of this expensive implants 
in the treatment of LSS as a stand-alone decompressive device.
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The Felix Trial: 
cost-utility analysis.
Extracted from Spine J. 2014. Part of the NASS Most Valuable Paper 2014.
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Background: In the 1980s a new implant was developed to treat patients with 
intermittent neurogenic claudication (INC) caused by lumbar spinal stenosis (LSS). 
This implant is now widely used. 
Purpose: The objective of this study is to determine whether a favourable cost-
effectiveness for interspinous process devices (IPD) compared with conventional 
bony decompression is attained.
Study design/setting: Cost-utility analysis was performed alongside a double-
blind randomized controlled trial.  5 neurosurgical centers (including one academic 
and four secondary level care centers) included participants for this study.
Patient sample: 159 patients with lumbar spinal stenosis were treated with the 
implantation of IPD and with bony decompression. 80 participants received an IPD 
and 79 participants underwent spinal bony decompression.
Outcome measures: Outcome measures were quality-adjusted life-years and 
societal costs in the first year (estimated per quarter), estimated from patient 
reported utilities (US and Netherlands EuroQol 5D (EQ 5D) and EuroQol Visual 
Analogue Scale (EQ VAS)) and diaries on costs (health care costs, patient costs, and 
productivity costs).
Methods: All analyses followed the intention-to-treat principle. Given the statistical 
uncertainty of differences between costs and QALYs, cost effectiveness acceptability 
curves graph the probability that a strategy is cost effective, as a function of 
willingness to pay. Paradigm Spine funded this trial, but did not had any part in 
data-analysis or the design and preparation of this manuscript.
Results: According to the EQ-5D, the valuation of quality of life after IPD and 
decompression was not different. Mean utilities during all four quarters were – not 
significantly – less favourable after IPD according to the EQ-5D with a decrease in 
QALYs according to the US EQ 5D of 0.024 (95% confidence interval -0.031 to 0.079). 
From a health care perspective the costs of IPD treatment were higher (difference 
€3,030 per patient, 95% interval €561 to €5,498). This significant difference is mainly 
due to additional cost of implants of €2,350 apiece. From a societal perspective, a 
non-significant difference of €2,762 (95% confidence interval -€1,572 to €7,095) in 
favour of conventional bony decompression was found. 
Conclusions: Implantation of IPD as indirect decompressing device is highly 
unlikely to be cost-effective compared with bony decompression for patients with 
intermittent neurogenic claudication caused by lumbar spinal stenosis.





The average increase in age of the general population results in a growing older 
population, and thus to an increase in incidence of patients with intermittent 
neurogenic claudication (INC) caused by lumbar spinal stenosis (LSS).1-3 INC is a 
complex of symptoms including pain in – frequently – both legs provoked by 
prolonged walking and standing and diminishes by flexion of the lumbar spine 
(such as in sitting position or when cycling). 1-3 Accompanying back pain is also 
associated with INC.4 The number of surgical interventions for lumbar stenosis 
increases– concomitantly with the increase in age of the general population 
– , and eventually this can lead to an increase of the use of implants.5-7 In the 
beginning of the 21ste century, a 15-fold increase of spinal surgeries with fusion 
techniques was reported.5-7 One of the possible explanations for this dramatic 
increase of fusion procedures was the development of new devices in the end 
of the 20th century. 
In 1984 an implant to indirectly decompress the lumbar spinal canal was 
developed.8;9 The implant is placed between the spinous processes, and is therefore 
called interspinous process device (IPD). The operation time was proposed to be 
shorter with less bony destruction and the technique was meant to accustom day 
surgery protocols, resulting in a shorter rehabilitation period after surgery. The 
implant was believed to be ideal for the old and even octogeneric patients with 
lumbar spinal stenosis. Despite the high costs of the implants and the high rate 
of implantations of IPDs, clinical trials comparing IPD’s with the golden standard 
(bony decompression) were not performed.10;11 The scientific evidence published 
until 2004 showed that the use of IPDs was superior compared – only – with 
conservative (no intervention) treatment. 12;13
A lot of different interspinous process devices (IPDs) have been introduced since 
1984.14-17 Since 1984, no good estimation of the total costs for society of these 
IPDs has been performed. In the systematic review published in 2011, at least 
20 different IPDs were identified.18 The two most studied implants are the Coflex 
implant (Paradigm Spine) and the X-stop (Kyphon inc and Medtronic).12-17;19-29 The 
Coflex implant – like the other IPDs – was used as stand-alone and subjected to 
our protocol as such. Currently the Coflex is in the US only approved for add-on to 
decompression. However, little is known about the costs of these regularly used 
implants. The 2007, worldwide sale of the X-stop implant was 80 million USD.30 In 
2009, 13,128 Coflex implants were used.31 Usually they are sold for - at least 2,500 
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USD, resulting in a total worldwide sale of at least 30 million USD in 2009. Other 
financial information was not accessible for the authors.
  In our clinical study we have shown that the use of interspinous implants compared 
to conventional decompression did not result in the hypothesized better outcome 
and not even in shorter recovery times. Moreover, it was demonstrated that the 
reoperation rate was significantly higher in the patients that had received an IPD.32 
The clinical outcome at 8 weeks and 1 year after surgery was comparable in both 
patient groups. The higher costs of IPDs in combination with the comparable 
results after one year and the higher re-operation rate do not seem to support the 
use of IPDs from an economical point of view. However, quality of life estimates 
and a complete cost overview could lead to another conclusion. In the present 
study we perform the cost-utility study alongside a clinical trial on this subject, to 




Patients between 40 and 85 years with at least three months of intermittent 
neurogenic claudication (INC) due to single or two level, degenerative lumber 
canal stenosis and an indication for surgery participated in a multicenter double 
blinded randomised controlled trial that compared treatment with IPD versus 
standard conventional surgical decompression.33 Patients with INC based on LSS at 
L5-S1 were excluded. Institutional Ethical Review Boards of participating hospitals 
approved the research protocol and participants gave written informed consent. 
A total sample size of 160 was calculated, based on a minimal clinically important 
difference of 20% change in the overall success rate according to the Zurich 
Claudication Questionnaire (ZCQ) between IPD and standard bony decompression 
in favor of IPD.34-36
Between October 2008 and September 2011, 162 patients with INC due to spinal 
stenosis were enrolled and 159 patients were analysed. A randomized design 
with variable block sizes was used, with allocations stratified according to center. 
Allocations were stored in prepared opaque, coded and sealed envelopes. The key 
was only accessible to the ProMISe data management system of the Department 
of Medical Statistics and BioInformatics of the Leiden University Medical Center. 




All patients gave informed consent. After induction of anesthesia the prepared 
envelope was opened and randomized allocation to one of the treatment arms 
was performed. 80 patients were allocated to IPD and 79 decompression surgery 
alone. Three patients were excluded after randomization; one patient died while 
waiting for the operation and two patients had a severe spondylolysis at the final 
preoperative check-up and were excluded from the study, because this could cause 
a detrimental effect in the implant group. Both groups were comparable regarding 
their baseline characteristics.32
Patients with a cauda equina syndrome, a herniated disc needing discectomy, 
history of lumbar surgery, or significant scoliosis (Cobb angle >25°) or other spinal 
deformities were excluded. The details of treatment can be found elsewhere.33 
Briefly, in patients in the IPD group an interspinous process device was implanted 
by a posterior midline approach using radiographic examination for localization of 
the appropriate level. No bony decompression was performed. In patients in the 
decompression group a partial resection of the adjacent laminas was executed, 
followed by a flavectomy with bilateral opening of the lateral recess. Patients and 
research nurses were kept blinded to the allocated treatment throughout the 
complete follow-up period of one year.
Utilities and QALYs
Utilities represent the valuation of the quality of life of the patients on a scale from 
zero (as bad as death) to one (perfect health). Patients described their quality of life 
using the EuroQol classification system (EQ-5D) from which we calculated utilities 
for the United States and the Netherlands.37;38 The EQ-5D provides societal valuation, 
which is preferred for economic evaluations from a societal perspective. In addition, 
we obtained valuations by the patients themselves, using a visual analogue scale 
(EQ VAS) ranging from zero (worst imaginable health) to 100 (perfect health). We 
transformed these valuations to a utility scale, using the power transformation 1-(1-
VAS/100)1.61.39 We obtained measurements for EQ-5D and the VAS at randomisation, 
and 2, 4, 8, 12, 26 and 52 weeks after randomization. For the EQ-5D and VAS 
measurements, respectively 3.4% and 3.2% of the items were missing. From the 
area under the utility curves we calculated the average utility during each separate 
quarter of the year after randomisation and during the entire year (QALYs).




We estimated the costs from the societal perspective during the one year of follow-
up. Because of this one-year time horizon, costs were not discounted. Costs were 
converted to 2013 price level using the general Dutch consumer price index.40 
Using cost diaries, patients reported admissions to hospital, visits (specialists, 
general practitioner and physical therapy), home care, paid domestic help, informal 
care, drugs and aids, out of pocket expenses as result of intermittent neurogenic 
claudication, and hours of absenteeism from work. At the follow-up at 4, 8, 26 and 
52 weeks after randomization the research nurse went through the diary with the 
patient. For these follow up moments 0%, 1.9%, 2.5% and 2.5% of the diaries were 
missing, respectively. 
In the costs of surgery we account for costs of depreciation and sterilisation of 
surgical instruments, costs of the operation room (including personnel) based on 
the duration of the surgery, and costs of the implant(s) in the IPD group, as these 
are the costs that differ between both procedures. Costs of use and sterilization 
of surgical instruments amount to €84.30 and €39.52 for IPD and decompression 
respectively. Costs of the operation room per minute of use were based on the 
average costs in 6 Dutch hospitals, resulting in an estimate of €18.74 per minute.41 
Costs of the implant are €2350 apiece; in some patients two implants were used. 
For other health care costs, we used Dutch standard prices, designed to represent 
societal costs and to standardize economic evaluations.42;43 Health care costs are 
reported including the patients’ time and travel costs. We valued the reported hours 
of absenteeism from work during the one year follow-up period according to the 
friction cost method using a friction period of 22 weeks, at standard productivity 
costs of € 28 per hour for women and €35 per hour for men, corrected for elasticity 
of labour time of 0.8 indicating that a reduction of labour time causes a less than 
proportional decrease in labour productivity. 42;43
Analysis
All analyses followed the intention-to-treat principle. Statistical analyses were 
conducted with Stata 11.2 (StataCorp, College Station, TX, USA). To reduce possible 
bias due to missing data, we used multiple imputation by chained equations, with 
10 iterations for the switching regression model.44 For each missing utility item or 
cost item, an imputation regression model was used that included the patient’s 
age, sex, randomisation group, and all (other) utility and cost measures at all (other) 
moments. Group differences in QALYs and costs were statistically analysed using 




standard unequal-variance t-tests. Base case cost-utility analysis compared one-
year societal costs to one-year QALYs based on the US EQ-5D. Sensitivity analyses 
were performed on the use of different utility measures (NL EQ-5D or EQ VAS), 
and on the perspective (societal or healthcare perspective). Depending on the 
willingness to pay for obtained effectiveness, a strategy is cost-effective compared 
with an alternative strategy if it has a better average net benefit (willingness to pay* 
QALYs – costs). Given the statistical uncertainty of differences between costs and 
QALYs, cost effectiveness acceptability curves graph the probability that a strategy 
is cost effective, as a function of willingness to pay.
Results
Utilities and QALYs
According to the EQ-5D, the valuation of quality of life after decompression was 
equal or better than after IPD (figure 1). Mean utilities during all four quarters were 
consistently less favourable after IPD (table 1). The difference in QALYs according 
to the US EQ-5D was 0.024 (95% confidence interval - 0.031 to 0.079), for the NL 
EQ-5D 0.032 (- 0.036 to 0.100). Thus, the difference in QALYs in the first year after 
treatment between both groups was not significant.
According to the EQ-VAS only in the first quarter and last quarter of the first year 
after treatment the quality of life was valued higher in decompression patients, 
while in the second and third quarter the IPD patients had a higher quality of life. 
QALYs based on the EQ VAS show a mixed picture during the first year, resulting in 
a non-significant difference of 0.010 (−0.047 to 0.067) in favour of decompression.
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Figure 1. Utilities according to US EQ-5D, NL EQ-5D, and EQ VAS
   US EQ-5D IPD;     US EQ-5D Decompression;
   NL EQ-5D IPD;     NL EQ-5D Decompression;
   VAS IPD;     VAS Decompression









































Willingness to pay per QALY (*  1000) 
   US EQ-5D, societal perspective;     US EQ-5D, health care perspective
   NL EQ-5D, societal perspective;     NL EQ-5D, health care perspective












1st quarter 0.731 0.739 -0.008
2nd quarter 0.729 0.759 -0.030
3rd quarter 0.724 0.762 -0.038
4th quarter 0.735 0.754 -0.018
QALYs 0.730(0.183) 0.753(0.166) -0.024 0.40
NL EQ-5D
1st quarter 0.702 0.717 -0.015
2nd quarter 0.697 0.738 -0.041
3rd quarter 0.694 0.742 -0.048
4th quarter 0.707 0.732 -0.025
QALYs 0.700(0.227) 0.732(0.205) -0.032 0.35
EQ VAS
1st quarter 0.776 0.755 0.021
2nd quarter 0.756 0.799 -0.043
3rd quarter 0.755 0.783 -0.029
4th quarter 0.765 0.753 0.012
QALYs 0.763(0.192) 0.773(0.164) -0.010 0.74
Healthcare costs
The average costs of IPD treatment including hospital stay in comparison to the 
decompression were €2,302 higher per patient (95% confidence interval €1,857 to 
€2,747). This significant difference is mainly due to additional cost of implants of 
€2,350 apiece. In the first year after treatment 21% of the IPD patients underwent 
resurgery in comparison with only 6% of the patients in the decompression group, 
resulting in (non- significant) higher costs of resurgery for IPD patients of €198 per 
patient (-€112 to €507). In total, mean health care costs per patient in the first year 
are €10,210 for IPD and €7,180 for decompression patients; the difference of € 3,030 
is significant (95% confidence interval €561 to €5,498). 
Societal costs
The productivity costs in this population with older patients, did not differ 
significantly between both study groups (respectively €3,171 for IPD and € 3,374 for 
decompression). Also the total non-healthcare costs, which are mainly determined 
by the productivity costs, were not significantly different: the total non-healthcare 
costs were on average €268 (95% confidence interval -€2,589 to €3,125) lower for IPD 
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patients. Combining the total healthcare and non-healthcare costs results in total 
societal costs of €13,858 per IPD patient and €11,096 per decompression patient in 
the first year after treatment. The difference of €2,762 has a 95% confidence interval 
of -€1,572 to  €7,095, and is therefore not significant.
Cost-utility analysis
The combination of (non-significant) higher societal costs and less favourable QALY 
outcomes (not significant) after IPD result in a small probability that IPD is more cost-
effective compared to decompression (figure 2). For any value of the willingness-to-
pay for a QALY the probability that IPD is more cost-effective than decompression 
is far below 50%. These results hold for all outcome measures (US EQ-5D, NL EQ-5D 
and VAS).  From a healthcare perspective in which IPDs are significantly more costly, 
the superiority of decompression is even more clear . This leads to the overall result 
that simple decompression is more cost-effective than IPD. 
Discussion
The Felix trial did not show advantage of IPD treatment as indirect decompressing 
device over conventional decompression.32;33 In addition the economic evaluation 
showed less favourable QALY outcomes (not significant) after IPD. Healthcare 
costs were higher for IPD treatment as indirect decompressing device compared 
to decompression. From a societal perspective the cost of IPD treatment were 
also higher, though not significant. In conclusion, implantation of IPD as indirect 
decompressing device is highly unlikely to be cost-effective compared with bony 
decompression for patients with intermittent neurogenic claudication caused by 
lumbar spinal stenosis.
The higher costs of IPD treatment were mainly due to the costs of initial surgery. A 
major component of the costs of IPD treatment is the cost of implants of €2,350. 
In 27% of the patients in the IPD group even two implants were used since there 
were two symptomatic levels to be treated. The operating time in the IPD group 
was a bit shorter (24 vs 43 minutes). However, this did not result in a significantly 
shorter overall time in the OR (e.g. including anesthesia and preparations time). 
Furthermore, the substantially higher repeat surgery rate, leaded to higher costs 
in the IPD group compared to the conventional group.32 However, the difference 
in costs of reoperation per patient was not significant, due to the fact that the




Table 2. Mean healthcare costs and societal cost per patient . 
Cost item IPD (N= 80) BD (N=79) Difference














Total (SD) 100 4713 100 2411 2302 <0.01
Repeated surgery (1 yr)# 21 447 6 250 198 0.21
Physical therapy 91 2431 92 2178 253 0.71
Other hospital admissions 22 868 6 300 569 0.14
Neurologist† 0.9 108 0.6 70 38 0.30
Neurosurgeon† 1.4 164 0.9 100 64 0.06
Orthopaedist† 0.7 82 0.4 42 40 0.19
Other specialists 55 250 59 236 14 0.85
Imaging 68 286 57 245 41 0.41
Pain relief 11 24 11 24 1 0.96
General practitioner† 4.0 173 3.9 166 7 0.86
Home care‡ 18 522 31 1000 -477 0.27
Drugs 62 65 70 85 -20 0.55
Aids 25 76 26 77 -2 0.98
Total healthcare costs
1st quarter 5963 3779 2184
2nd quarter 2120 1660 460
3rd quarter 1063 871 193






Paid domestic help‡ 13 172 9.4 128 44 0.62
Informal care‡ 20 276 30 406 -130 0.53
Out of pocket expenses 6.5 30 4.6 8 21 0.33
Productivity costs (friction) 
1st quarter ‡ 31 1339 39 1665 -326
2nd quarter ‡ 30 1294 22 944 350
3rd quarter ‡ 6.5 279 11 475 -196
4th quarter ‡ 6.0 259 6.8 290 31













1st quarter 7437 5676 1760
2nd quarter 3522 2700 822
3rd quarter 1460 1453 7






* t test for unequal variance, correcting for non-response using multiple imputation; ¶ Number of hospital 
days; † Number of visits; ‡ Number of hours; # percentage of patients actually operated on within twelve 
months after randomization. BD bony decompression
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costs of reoperation were higher for decompression patients and the variance 
in costs between patients. The operation time of simply removing an implant 
and performing a standard bony decompression is much shorter compared to a 
reoperation in a surgical field with scar tissue. The total health care costs in the first 
year of €10,210 per patient were significantly higher for IPD group compared to the 
decompression group (€7,180).
Mean productivity costs were low in this study (€ 3,171 per patient in the IPD 
group and €3,374 in the decompression group), due to the fact that the majority 
of patients were retired: 71% of patients in the decompression group and 78% 
of patients in the IPD group did not report productivity costs. Due to the large 
variance (a minority of patients having productivity costs) the difference of € 203 
was not significant. As a result, also the non-healthcare costs in the first year, mainly 
consisting of productivity costs, were not significantly different in favour of the 
IPD group (€3,648 per patient versus €3,916 per patient in the decompression 
group). Taking the healthcare and non-healthcare costs together in the societal 
costs resulted in non-significant higher costs for IPD patients of €13,858 compared 
to €11,096 in decompression patients. The combination of (non-significant) higher 
costs and less favourable QALY outcomes (not significant) after IPD resulted in a 
small probability that IPD is more cost-effective compared to decompression.
As it is highly unlikely that IPD as indirect decompressing device is more cost-
effective than decompression, the high costs for society of these implants in the 
recent years could not be justified based on the current clinical study. Implants 
were already widely used for more than twenty years throughout the world for 
different indications resulting in high worldwide sales. Cost utility analysis of these 
implants was not performed earlier. The recently published FDA Trial, in which 
IPDs in combination with bony decompression were more effective compared 
to bony decompression in combination with spinal fusion, did also not include 
a societal cost-analysis.45 In the future, new products and procedures should be 
subjected to rigid scientific comparison with current gold-standard treatments 
before introduction.
This study has several limitations. Firstly, we limited the duration of the economic 
evaluation to one year. However, differences in utility values and costs between the 
groups decreased in the last quarters, indicating that the most important effects 
are included in the one year study period. Furthermore, the generalizability of our 
results may be difficult due to the high amount of different implants and different 
selling prices of these implants. Using lower prices of the implants did however not 




alter the results. Even if we assumed no costs for the implants, the probability that 
IPD as indirect decompressing device was more cost-effective than decompression 
was lower than 50% for values of the willingness to pay commonly accepted in 
The Netherlands (€20,000-€40,000). This can be explained by the fact that IPD did 
not result in a higher quality of life and also not to significant savings in other 
costs. In the future, new products and procedures should be subjected to rigid 
scientific comparison with current gold-standard treatments before introduction. 
As mentioned earlier, selection bias could have been introduced through the 
opinion of the including neurosurgeon that patients with relatively high co 
morbidity should not be offered an IPD. Perhaps, the supposed shorter (hospital) 
recovery and related costs could have been more clear in this study if we had 
included older patients or patients with more co-morbidity in a study design under 
local anesthesia. However, blinding of the patient would not be possible. Therefore 
we decided to perform a robust double blind comparison.33
Conclusion
Implantation of IPDs as indirect decompressing device leads to higher healthcare 
costs and do not improve quality of life after treatment compared with standard 
bony decompression. Therefore, implantation of IPD as indirect decompressing 
device is highly unlikely to be cost-effective compared with bony decompression. 
The use of these implants over the past three decades could therefore not be 
justified based on this study.
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Background: Magnetic resonance imaging (MRI) is an important tool to confirm 
the diagnosis of lumbar spinal stenosis (LSS) as a cause for intermittent neurogenic 
claudication. It is believed that the narrowness of the lumbar spinal canal correlates 
to the severity of complaints, and that it may be a good predictor of clinical outcome 
if treated. However, this hypothesis has never been (prospectively) tested.
Methods: We studied baseline MRIs of 155 patients with intermittent neurogenic 
claudication and lumbar spinal stenosis. MRI and patient data were gathered for a 
randomized trial comparing bony decompression to implantation of an interspinous 
process device as surgical treatment options for LSS. Three independent specialized 
readers were asked to evaluate the MRIs to grade narrowing (Schizas scale) and to 
judge likelihood of cauda compression on the relevant spinal levels. Additionally, 
several other stenosis-related characteristics were scored. Symptom severity at 
baseline and at one-year follow-up were quantified using the Modified Roland 
Disability Questionnaire (MRDQ), the Visual Analogue Scale (VAS) for leg pain, and 
VAS for back pain. The radiological scores were correlated with clinical baseline 
and outcome scores to assess diagnostic and prognostic value of MRI findings at 
baseline.
Results: There was good agreement on the clinically relevant level of lumbar spinal 
stenosis (kappa range 0.57 to 0.64). MRI assessment of grading of compression 
(kappa of agreement ranges 0.33-0.46) did not correlate with baseline MRDQ, nor 
with outcome based on postoperative change in MRDQ (p-value 0.61). However, 
both absence of epidural fat and presence of tortuous caudal nerves on MR images 
(kappa of agreement ranges 0.53-0.72 and 0.67-0.70 respectively) in patients with 
LSS were relatively good predictors for satisfactory recovery after surgery (p-values 
0.03 and <0.01 respectively). 
Conclusion: The grading of compression on the preoperative MRI is neither 
ambiguous nor correlating to severity of clinical condition. It does furthermore 
not have the ability to predict the outcome after one year if surgically treated. MRI 
should therefore only be used to appoint the pathological level in case surgical 
decompression is considered.
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Background
Since the early publications of Verbiest et al. in 1950 on spinal stenosis, intraspinal 
diameter is believed to be one of the most important factors influencing severity 
of symptoms in patients with intermittent neurogenic claudication (INC) caused by 
lumbar spinal stenosis (LSS).1 Most patients with INC have a complex of symptoms, 
dominated by leg pain (frequently in both legs), which may be exacerbated by 
walking, prolonged standing or lumbar extension.1-4 The extent of compression 
was first measured in vivo in 1950s: small antero-postero diameter (smaller than 
12 mm at L5) was considered prone for development of INC.3 Myelography, later 
computed tomography (CT) imaging and nowadays magnetic resonance imaging 
(MRI) are used to assess the presence of and the level at which compression exists.5 
It is generally believed that the relative size of cross-sectional area of the dural 
sac correlate with clinical symptomatology is not known, though this was never 
(prospectively) evaluated before.6-10 Narrowness of the lumbar spinal canal is 
common in the elderly spine: 20% of subjects in the healthy population (median 
age 66 years) were found to have severe stenosis on MRI.6, 7, 10 However, none of these 
subjects had any complaints. Furthermore, abnormalities related to degenerative 
spinal disorders, such as lumbar spinal stenosis to any extent, or herniated discs, 
are found in up to 64% of MRIs made in asymptomatic populations, indicating a 
generally weak clinico-radiological correlation.11 
The clinical short-term and long-term follow-up of a double blind multicenter 
randomized controlled trial comparing interspinous process devices (IPD) and 
bony decompression to treat patients with INC  caused by LSS was recently 
published.12 Patients with lumbar spinal stenosis, and failed conservative treatment 
were included for this trial, and were therefore ideal subjects to select for imaging 
studies comparing INC complaints with MRI parameters.12 Prior to both treatment 
modalities, baseline MRI was obtained for all patients.13 This provided us with a large 
set of MRIs in combination with a standardized evaluation of clinical condition of 
intermittent neurogenic claudication at baseline and during follow up after surgical 
intervention. The goal of this study was to assess whether stenosis severity as 
seen on baseline MRI correlates to clinical condition at baseline and whether MRI 
parameters correlate to the outcome one year after surgery. 





Patients in this study were participants in the Felix Trial, a double-blind multi 
center randomized trial among patients with a history of intermittent neurogenic 
claudication (INC) based on LSS, as seen on MRI. Patients included in the trial were 
aged 40 to 85 years and were subjected to at least 3 months of conservative therapy. 
The medical ethics committee at each of the five participating hospitals approved 
of the Felix Trial protocol (including the use of the MRI for scientific purposes), which 
is available with the full text of this article at BMJ.com.12, 13 Written informed consent 
was obtained from all patients.
MRI protocol and evaluation
All patients included in the trial underwent MRI at time of initial diagnosis. The 
extent of spinal stenosis was graded according to the grading system for spinal 
stenosis developed by Schizas et al.14 The grading system allows for the classification 
of lumbar spinal stenosis in four grades: grade A, no or minor stenosis; grade B, 
moderate stenosis; grade C, severe stenosis and grade D, extreme stenosis. Grade 
A is further divided into four subcategories (Figure 1).14 In our analysis we used the 
four category Schizas scale (grades A, B, C and D) and two dichotomized Schizas 
scales (whereas grade A was scored as ‘no to mild stenosis’ and grade B, C and D 
were scored as ‘stenosis present’ and the alternative whereas grade A and B were 
scored ‘as no to mild stenosis’ and grade C and D were scored as ‘stenosis present’). 
Presence of tortuosity of the caudal nerves and presence or absence of epidural 
fat were also scored. Facet hypertrophy was assessed using the recommended 
grading system developed by Weishaupt et al., which ranges from grade 0, no facet 
hypertrophy, to grade 3, severe hypertrophy (Figure 1).15, 16 
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Figure 1.1. Schizas scale
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MRIs were performed at each study center using a standardized protocol tailored 






 axial images were obtained, 
using 3 mm contiguous slices in all directions and an in-plane resolution of 1mm2 
or less. Two experienced neuroradiologists and one neurosurgeon dedicated to 
spine surgery independently evaluated all MRIs. The 3 readers were not provided 
with any clinical information of the included patients. Prior to the evaluation of 
MRIs the readers met once to evaluate and refine the MRI definitions. The blinded 
readers were unaware of the spinal level that was operated on and evaluated the 
images uniformly and independently from each other. First, the readers had to 
decide which levels showed most compression and were most likely to be clinically 
relevant (and thus in need of decompression). 
Figure 1.2 – Weishaupt scale
Grade Criteria
0 Normal facet joints space (2-4 mm width)
1 Narrowing of the facet joints space (<2mm) and/or small osteophytes and/or mild 
hypertrophy of the articular process
2 Narrowing of the facet joints space and/or moderate osteophytes and/or moderate 
hypertrophy of the articular process and/or mild subarticular bone erosions.
3 Narrowing of the facet joints space and/or large osteophytes and/or severe hypertrophy of 
the articular process and/or mild subchondral cysts.
Outcome
All assessments obtained from MRI were compared to continuous outcome 
measures used in the Felix Trial.12, 13 Continuous outcome measures obtained at 
baseline and after one year were used in order to evaluate if the MRI assessments 
correlated to baseline clinical condition and whether they could serve as a predictor 
for outcome after one year.12, 13 Consequently, the primary clinical outcome scale 
for this study was the Modified Roland Disability Questionnaire (MRDQ) for sciatica 
(scores range from 0 to 23, with higher scores indicating worse functional status). 
17-25 This continuous clinical outcome scale was used in all analyses except for the 
receiver-operating-characteristic ROC analysis where the dichotomized MRDQ 
(change of 4 or less in poor results and over 4 in good results) was used.21-23 The 
100mm visual-analogue scale (VAS) back pain and VAS leg pain (with 0 representing 
no pain and 100 the worst pain ever experienced) were also assessed.26-28 
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Interaction of treatment arms on predictive value of MRI measurements
Patients in the Felix trial were treated using an interspinous implant without bony 
decompression or with bony decompression.13 Baseline scores and one-year results 
based on MRDQ and VAS leg and VAS back pain were comparable in both treatment 
arms.12 Multivariate analyses with regression techniques were used  in order to 
adjust for potential confounding of effect modifying of the allocated treatment. 
Statistical analysis
The majority opinion of the three readers regarding the MRI characteristics (answered 
independently by at least two of the three) was used in the statistical analysis. 
If all reviewers had a different opinion, decision was made by a group decision. 
Interobserver agreement regarding the MRI findings was determined with the use 
of absolute percentages (e.g. regarding clinical level) and kappa values (weighted 
in cases of ordered data). Mean scores on MRDQ and VAS back pain and VAS leg pain 
were correlated to MRI findings stratified according to the extent of compression 
according to Schizas. An analysis of the receiver-operating-characteristic (ROC) 
curve is only possible with a dichotomized (MRDQ) outcome scale. Mean scores 
on VAS back pain were correlated to the extent of facet hypertrophy. In a subgroup 
analysis, MRI characteristics were compared between patients treated with bony 
decompression and patients treated with an IPD without bony decompression.
Differences between groups for the clinical continuous data (e.g. MRDQ, VAS leg and 
back pain) were assessed by one-way ANOVA and regression techniques. Patients 
with missing MRDQ values at one year and baseline were excluded. Analysis of the 
receiver-operating-characteristic (ROC) curve was used to assess the diagnostic 
accuracy of ordinal baseline MRI findings (7 point, 4 point and dichotomized 
Schizas scale) for a favourable outcome, based on the MRDQ, at 1 year. The area 
under the ROC curve (AUC) ranges from 0 to 1 and provides a measure of a test’s 
ability to discriminate between participants who have the outcome of interest and 
those who do not.29 A test that correctly classifies all participants has an AUC of 
1.0, and a test with no discriminatory value has an AUC of 0.5.29 ROC curves were 
used to determine a cut-off value for a clinical test; therefore, ROC curves could 
not be used for the presence of epidural fat or the presence of tortuous caudal 
nerves. In logistic-regression models, the association between MRI findings and 
clinical outcome was adjusted for randomized treatment and treatment received. 
Furthermore, a subgroup analysis was performed by adding the term of ‘stenotic 
level agreed by all readers’ to the statistical analysis of dichotomized good outcome 
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based on the MRDQ. Statistical analysis were performed using SPSS software version 
20. The level of statistical significance were set at 0.05.
Results
Patients
159 participants with INC due to lumbar spinal stenosis at one or two levels with 
an indication for decompressive surgery were blindly randomized into two groups: 
80 participants received an interspinous process device (IPD) and 79 participants 
underwent spinal bony decompression. Results on a baseline MRI were available 
for 155 patients (97%). Baseline characteristics are shown in Table 1.
Readers
All three reviewers agreed (blinded for the later to be operated level) on the 
stenotic (symptomatic) lumbar level in 90 out of 159 patients (58%). Moderate-to-
substantial agreement was found for the MRI assessment of the relevant stenotic 
(symptomatic) level (kappa range 0.57 to 0.64). The combined kappa for the fully 
agreed marked stenotic level compared to the operated level was 0.87. Decision 
on clinical symptomatic lumbar level by majority was possible for the remaining 
patients (‘majority opinion’). If compared to the level patients were operated upon 
in the Felix Trial, the majority opinion of the most stenotic (symptomatic) level the 
kappa for agreement was 0.70 (good agreement).
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Table 1. Characteristics of the patients at baseline
Characteristic (n=155)
Median Age –years (range) 66 (44-83)
Male sex – no. (%) 82 (53)
Median duration of INC –months (range)* 19 (1-204)
Median BMI (range)# 29 (20-48)

















Roland Disability Questionnaire 23 points (SD) 13.8 (5.0)
Mean mm VAS leg pain (SD)$$ 56 (24)
Mean mm VAS back pain (SD)$$ 49 (26)
* Duration of intermittent neurogenic claudication (INC) in months; # Bodily-mass index is the weight in ki-
lograms divided by the square of the heights in meters; $ based on consensus (at least two reviewers agreed 
on the relevant clinical level; $$ The intensity of pain was measured by a horizontal 100mm visual-analogue 
scale (VAS), with 0 representing no pain and 100 the worst pain ever. 





















A Mean 16 58 56 -7 -13 -22
N 7 10 10 7 9 9
SD 4 20 30 5 39 45
B Mean 13 57 50 -4 -27 -17
N 24 24 24 21 23 23
SD 5 23 25 6 34 27
C Mean 14 54 44 -8 -37 -23
N 59 63 63 57 62 62
SD 5 24 27 6 28 26
D Mean 14 53 53 -9 -39 -34
N 31 32 33 30 32 33
SD 5 26 25 6 31 29
Total Mean 14 55 48 -7 -34 -25
N 121 129 130 115 126 127
SD 5 24 27 6 31 29
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1,00 Mean 15 50 61 -7 -11 -7
N 3 7 7 3 6 6
SD 2.5 25 33 7 40 40
2,00 Mean 14 53 47 -6 -26 -24
N 43 45 45 41 43 43
SD 6 26 29 6 31 24
3,00 Mean 14 58 49 -8 -40 -26
N 80 83 84 75 83 84
SD 5 22 24 7 29 29
Total Mean 14 56 49 -7 -34 -25
N 126 135 136 119 132 133
SD 5 24 26 6 31 28
N: number of patients in group; # Difference between baseline and 52 weeks MRDQ values; SD Standard 
Deviation
Table 3. interaction of MRI characteristics and clinical signs at baseline and one-year follow-up


















Schizas scale 0.61 0.86 0.26 0.03 0.09 0.13
Weishaupt scale 0.77 * 0.43 0.44 * 0.26
Presence of tortuous 
caudal nerves
0.19 0.27 0.45 <0.01 0.08 0.04
Absence of epidural fat 0.35 0.99 0.11 0.03 0.05 <0.01
$ p-values as interaction of MRI characteristics and clinical outcome estimated by linear or logistic regres-
sion models; N: number of patients in group; # Difference between baseline and 52 weeks MRDQ values; 
## Difference between baseline and 52 weeks VAS values; * not a relevant correlation and thus not tested.
MRI findings at baseline
The readers judged the grade of compression based on the Schizas scale:  4 patients 
with level A2, 4 patients with level A3, 2 patients with level A4, 24 patients level B, 64 
patients level C, and 36 patients level D (23 missing data for this item). The MRIs of 
these symptomatic patients were seldom scored with A, therefore the subdividing 
of grade A was not used in our analysis. The kappa of agreement of the Schizas scale 
was poor (kappa ranges 0.16-0.46). By comparison, the dichotomized Schizas scale 
(scale A and B versus scale C and D) kappa was somewhat better (kappa ranges 0.32-
0.59). Facet hypertrophy was present in the vast majority of patients: 86 patients 
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(63%) had severe hypertrophy (level 3) and 43 (31%) patients had moderate facet 
hypertrophy (level 2) and 8 patients (6%) had mild hypertrophy (level 1) based on 
the Weishaupt scale (18 missing data for this item). However, the scale’s kappa of 
agreement was very poor (range 0.09-0.34). Tortuous caudal nerves were seen on 
MRI in 45 patients (29%; kappa of agreement ranges 0.67-0.70). Absence of epidural 
fat tissue was seen in 51 patients (33%; kappa of agreement ranges 0.53-0.72).
Table 4. agreement among the readers 
A versus B A versus C B versus C
Agreement on most clinical stenotic level 0.57 (n=155) 0.62 (n=155) 0.64 (n=155)



















Facet hypertrophy based on Weishaupt scale# 0.09 (n=106) 0.34 (n=110) 0.11 (n=114)
Presence of tortuous caudal nerves 0.70 (n=155) 0.68 (n=155) 0.67 (n=155)
Absence of epidural fat# 0.59 (n=102) 0.72 (n=106) 0.53 (n=114)
A and C represent the two neuroradiologists, while B represents the neurosurgeon.
$ kappa values of agreement of reviewers’ measurements; N: number of patients in group; $ based on levels 
L3-L4 and L4-L5 whereas other levels were sporadic reports and thus not representative kappa values; $$ 
based on the dichotomized Schizas scale whereas A and B were scored as ‘no stenosis’; scales C and D were 
scored as ‘stenosis present’. # based on level L4-L5 whereas other levels were sporadic reports and thus not 
representative kappa values.
Association between MRI findings and baseline symptoms (diagnostic 
value of MRI)
The grade of stenosis based on the different types of Schizas scale did not correlate 
with functional status (MRDQ) at baseline (p-value 0.61) nor with VAS back pain 
(p-value 0.26) or VAS leg pain  (p-value 0.86)(Tables 2a & 3). The severity of facet 
hypertrophy according to the Weishaupt scale did not correlate with the clinical 
parameters MRDQ or VAS back at baseline. Tables 2b & 3). The presence of tortuous 
caudal nerves and the absence of epidural fat did not correlate to baseline clinical 
condition (p-values ranging 0.11-0.99).
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Figures 2.1 and 2.2 (above). with absence of epidural fat and caudal roots; 
Figure 2.3 (below).  MRI of a patient with Schizas C
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Association between MRI findings and clinical outcome (predictive val-
ue of MRI parameters)
There was a significant correlation between preoperative compression (based 
on the Schizas scale) and clinical outcome after 52 weeks MRDQ (p-value 0.03). 
However, this was caused by an opposite effect in the relative small group of 
patients in group A. When the Schizas scale was dichotomized (A and B scales for ‘no 
stenosis’  and C and D ‘stenosis present’) the correlation between the preoperative 
extent of compression and the MRDQ after 52 weeks disappeared (p-value 0.86). 
The grade of stenosis on the preoperative MRI (based on the Schizas scale divided 
in four subscales and dichotomized) did not correlate to the decrease in VAS leg 
pain over 52 weeks following surgery (p-value 0.09) nor to the decrease in VAS back 
pain (p-value 0.13)(Table 3).  Therefore, the grade of stenosis on the preoperative 
MRI is judged not to be a good predictor for clinical outcome defined as VAS leg or 
back pain one year after surgery. 
The preoperative observers’ ratings on the Schizas scale assessing the extent of 
stenosis on MRI did not distinguish between patients with a favourable outcome 
based on MRDQ outcome versus those with an unfavourable outcome (AUC 0.51; 
CI 0.40 to 0.62). The dichotomized MRDQ was used in order to perform an analysis 
of the receiver-operating-characteristic (ROC) curve. 
Figures 2 show two case-examples of a patient with severe stenosis (tortuosity 
of caudal roots and absence of epidural fat and a good clinical outcome (Figures 
2.1 and 2.2); versus a patient with moderate stenosis (Schizas C) and poor clinical 
outcome (Figure 2.3).
The severity of preoperative facet hypertrophy on the preoperative MRI is not a 
good predictor for the decrease in VAS back pain (p-value 0.26) during the 52 weeks 
following surgery (Table 3). The severity of facet hypertrophy did also not distinguish 
between patients with favourable outcome versus those with unfavourable clinical 
outcome based on MRDQ (p-value 0.44; AUC 0.52; CI 0.42 to 0.63). By contrast, 
absence of epidural fat and/or presence of tortuous caudal nerves on the baseline 
MRI were good predictors for good long-term clinical outcome (more than 4 points 
decrease on the MRDQ) in operated patients (p-values 0.03 and <0.01 respectively)
(Table 3). 67% of patients (SD 0.47) demonstrated good recovery (MRDQ decrease 
of more than 4 points) when all readers agreed on the clinical symptomatic level. 
54% of patients (SD 0.50) demonstrated good recovery (MRDQ) when not all readers 
agreed on the clinical symptomatic level (agreed by all reviewers p-value of 0.1).
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Interaction of treatment arms on predictive value of MRI measurements
MRDQ decreased from 13.0 at baseline to 6.9 after 52 weeks in the IPD group 
and from 14.4 at baseline to 8.1 after 52 weeks in the bony decompression group 
(p-value 0.28). VAS back pain decreased from 60 to 23 (IPD) and from 49 to 31 
(bony decompression) between baseline and 52 weeks (p-value 0.09). VAS leg 
pain decreased from 52 to 23 (IPD) and from 58 to 26 (bony decompression) 
between baseline and 52 weeks (p-value 0.54). Multivariate analysis on the 
possible confounding of the randomization groups did not result in any significant 
interaction with any baseline and one year outcome (predictive value) scales. 
Discussion
This is the first prospective study comparing baseline MRI findings with baseline 
complaints and long-term follow-up after surgical treatment. Inter-rater variability 
between readers for the MR parameters was relatively high in our study, –which 
is interesting given the good inter-observer reproducibility reported in the recent 
study on interpretation of herniated discs, by the same readers.30 Stenosis severity on 
baseline MRI correlated poorly with baseline functional measurements and did not 
distinguish between patients with favourable outcome and unfavourable outcome 
after decompression. Only presence of extreme compression at baseline (patients 
with absence of epidural fat and/or the presence of tortuous caudal nerves on 
their MR images) appeared to be a fairly good predictor of good clinical outcome 
after operation. Furthermore, these MR parameters showed good interobserver 
reproducibility, in contrast to the other MR parameters. As suggested by earlier 
MRI studies assessing lumbar spinal compression in patients without any clinical 
complaints, compression on MRI is no more than a sign supporting the complaints 
of the patient.7 Operating patients without significant complaints, even though 
they demonstrate compression on baseline MRI, is therefore not wise, and clinical 
symptoms should guide any decision on operation. 
MRI is viable to appoint the pathological level in case surgical decompression is 
considered. However,  the current study demonstrates that the potential of MRI 
to grade the extent of compression is poor, regarding the low kappa rates. Some 
studies have been performed before to evaluate the interobserver variability 
on the topic of radiological images in patients with lumbar spinal stenosis.31, 32 
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These studies could likewise not demonstrate a correlation between the extent 
of compression on the Schizas scale and baseline or outcome clinical condition: 
Schizas et al presented an interobserver agreement kappa of only 0.44, similar 
compared with the kappa range presented in this study14. Perhaps myelography 
alone, myelography combined with MRI, or new diagnostic modalities could help to 
solve these problem. Morita et al and Ogura et al concluded in retrospective studies 
(not correlated to baseline clinical condition or long-term outcome after surgery) 
that CT myelography is still superior or equal compared with MRI.32, 33 In favour of 
the combination of MRI and CT myelography are the data in a former retrospective 
study concluding that the interobserver correlation improved – slightly – by adding 
myelography to MRI. However, these authors could not demonstrate a correlation 
with clinical symptoms either.34 Paine et al presented their results on 95 consecutive 
INC patients with LSS on myelography in 1976 and reported 80% ‘good’ recovery 
and 11% ‘fair’ recovery 2,5 years after surgery.35, 36 Nowadays, diagnostics in INC 
patients with LSS are mainly performed with MRI with agreement of the relevant 
stenotic level on MRI of only 58% among highly experienced reviewers. Combining 
this finding with the observation that only 65% of the patients with INC have good 
recovery after surgery.12, 37-39 suggests that myelography is more accurate to diagnose 
clinically relevant LSS. Namely, a good diagnosis is highly likely to result in a high 
success percentage of treatment. An important shortcoming of this conclusion is 
that in 1976 the surgical decompression of the cauda equina was not as broadly 
implemented as it is nowadays: it is only logical to expect that only the severe cases 
made it to the myelographic evaluation and subsequent decompression. 
An important limitation of our study is that the included patients had maximal two 
stenotic lumbar levels. This was due to the design of the Felix Trial, in which it was 
not possible to implant patients with more than two IPDs.13  Secondly, outcome 
based on MRI findings were secondary outcome measurement in the original Felix 
Trial protocol.13 Sample size calculation of the trial was based on clinical outcome 
scales. It is debatable if we had enough power to give a final answer to our research 
question. Furthermore, this study has a potential selection bias due to the fact that 
all patients were operated. 
Finally, this study shows that future research in spinal stenosis surgery should also 
focus on diagnostic tools to diagnose stenosis. Further research may focus on 
the evaluation of the additive value of myelography to MRI evaluation of LSS. For 
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now, MRI should only be used to confirm the diagnosis of LSS in case the clinical 
condition is so invalidating that surgical decompression is considered. The patient 
should know that the success rate of the surgical intervention is only 65%, but that 
the chance on success is higher in case epidural fat is absent and/or tortuous caudal 
nerves are present.37-39
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The clinical introduction of novel medical devices and surgical techniques often 
occurs without evidence of good methodological quality and with relatively little 
oversight and regulation. As a consequence, the safety, efficacy and long-term 
effects of devices are frequently insufficiently known upon device approval. Recent 
controversies surrounding the PIP breast implants, metal-on-metal hip implants 
and interspinous implants underscore the need to reconsider how innovation in 
medical devices and surgical techniques can adhere to sound ethical standards 
without inhibiting surgical research and development. In this paper the introduction 
of spinal implants is taken as an example to firstly discuss the scientific and ethical 
challenges of developing, testing and introducing novel medical devices, and to 
secondly identify avenues for improving the existing regulatory frameworks for 
such innovation. Two measures for improvement are most feasible in the short-
term: demanding prospective studies before device introduction, and developing 
registries in order to monitor and evaluate new medical devices.





The clinical introduction of novel surgical techniques, particularly those using 
medical implant devices, often occurs with relatively little oversight and regulation.
[1] This is in contrast with the strong regulatory requirements that are in place for the 
introduction of novel pharmaceuticals. As a consequence the safety, efficacy and 
long-term effects of medical implant devices are often insufficiently known before 
they are used in patients.[1,2] Adoption of the novel device is frequently driven by 
other factors than evidence, such as the enthusiasm of the surgeon or marketing.
[3] Recent controversies surrounding the PIP breast implants, metal-on-metal hip 
implants and spinal implants underscore the need to reconsider how patients can 
be protected from ineffective, or potentially harmful, medical devices and surgical 
techniques without inhibiting surgical research and development (R&D).[4–12] 
In this paper the introduction of spinal implants is taken as an example to firstly 
discuss the scientific and ethical challenges of developing, testing and introducing 
novel medical devices, and to secondly identify avenues for improving the existing 
regulatory frameworks for such innovation. We argue that prospective comparative 
effectiveness studies should be mandatory before approval of a device, and that 
post-marketing surveillance for all medical devices, as proposed by the EU, should 
be introduced as soon as possible.[13,14]
History of spinal implants: the Interspinous Process Devices
Spinal implants are widely used for different indications, ranging from indisputable 
indications such as reconstruction of the destabilized spine by trauma and 
reconstruction after surgical resection of vertebral tumours, to less clear reasons such 
as stabilization for degenerative spinal conditions. Most implants are used for the 
latter group of degenerative spinal diseases, one of which is lumbar spinal stenosis 
(LSS). LSS is caused by arthrosis (degeneration) of the facet joints and development 
stenosis, which can result in lumbar nerve root compression. Removal of the bone 
and arthrosis around the nerve (bony decompression e.g. laminectomy) is the gold 
standard to treat LSS in the elderly population. The reported successful clinical 
outcome after bony decompression is only 64% and many patients remain to have 
associated low back pain.[15–18] In an effort to improve clinical outcome, a French 
group introduced a new non-rigid fixation (interspinous process devices (IPDs)) for 
patients with LSS and associated back pain in 1984: the Wallis system.[19–21] 
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The Wallis system implants were tested for durability in cadaveric studies and were 
first implanted in humans in 1986.[20] The results of these first procedures were 
retrospectively published.[20] Only after this period were patients included in a 
(non-comparative) prospective study, during which the device was implanted 
in over 300 patients. The study showed good recovery in 60% of patients.[21] 
After this study, commercial development of the system was started. While the 
research group was planning to perform a randomized controlled trial (RCT), such 
a prospective comparative study of this implant is not available in Pubmed.[20,21] 
After the introduction of this implant by Senegas, the development of other IPDs 
followed, such as Minns, X-stop and Coflex.[22–25] Cadaveric studies did not show 
any biomechanical difference between the various IPDs and they were therefore 
considered as interchangeable, although differences in clinical effectiveness were 
not investigated.[24] 
After introduction of these devices, various studies were conducted to test 
the effectiveness and safety of IPD treatment for LSS.  However, most of these 
studies did not compare the results with other interventions, and most did not 
have prospective study designs.[21,25,26] It took 30 years (from 1984 until 2013) 
until two prospective studies were published that compared IPD treatment with 
conventional (surgical) care.[16,27–30] These studies showed that treatment with 
IPD was not superior compared to bony decompression without implants and 
that IPD treatment resulted in a higher reoperation rate.[16,30] A third study was 
terminated because of the high number of reoperations (complications) in the 
experimental (IPD) group.[28] 
The problem of lacking evidence for IPD use extends beyond LSS. Nowadays there 
are multiple questionable indications for implantation of IPDs: some are used as 
stand-alone for LSS, others as adjuvant to surgical bony decompression for LSS 
in the hope to decrease back pain, and yet others to prevent disease at adjacent 
lumbar segments.[16,28,31] For these indications, IPDs remain in use without any 
evidence of treatment benefit. Furthermore, the lack of evidence for treatment of 
LSS extends beyond IPDs. Before the introduction of IPDs, lumbar spines that were 
“destabilized” after LSS were frequently rigidly stabilized by pedicle screws, and 
since the mid-nineties of the last century vertebral interbody cages were added to 
this process.[32–34] However, pedicle screws and discal interbody cages, whose 
use is widespread for LSS, were introduced without any evidence of added value 




compared with conventional surgical decompression without implants, or even 
any evidence of incidence of spinal instability.[35–37] 
Thirty years after the first introduction of IPDs for LSS, it is now clear that there is no 
justification for treating LSS patients with IPDs.[16] Although precise numbers about 
the number of implanted IPDs are not available, at least three hundred thousand 
patients have been implanted with these devices since their introduction.[38] 
How was it possible that patients were not protected from these harmful devices 
and society from the use of these costly implants by regulations or any other 
measurements?
Present regulatory practice in the EU and US
In Europe, what is needed since 1993 for market introduction of a device is the CE 
(‘Conformité Européenne’). The CE approval guarantees that implants do not fall 
apart or have harmful material in them. However, a CE approval will not guarantee 
that the medical device will work in patients, or that it does not cause harm in 
other ways, such as higher re-operation rates as compared to other interventions. 
Recently, the European Committee (EC) has begun to realize the inadequacy of these 
regulations and in 2013 released a recommendation for a common framework for 
a unique device identification system (a monitoring system or registry) of medical 
devices in the EU.[14] From 1990 till 2013 the EC launched several directives, 
recommendations and proposals to realize such an identification system for safe, 
effective and innovative medical devices. The first amending directive which urges 
for a registry dates from 1993.[13] However, none of these directives were ever 
implemented.[13] The suggestions made in the Commission Recommendation of 
2013 to assure traceability are sound, yet to this day, they remain just a proposal.[14]
The US Food and Drug Administration (FDA) has a stricter system for device approval, 
in which inventors are required to perform randomized studies before introduction 
of a device. However, the LSS case shows that this system also shows some 
shortcomings, since the FDA does not demand that the experimental treatment 
is compared with the gold standard.[6] IPD treatment with bony decompression 
is nowadays approved in the US, after the publication of an FDA study on IPD 
treatment.[27] However, this study did not compare the experimental treatment 
(IPD) with the gold standard (bony decompression), but with another experimental 
treatment (bony decompression with fixation techniques). This has happened 
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before in the spine research field: the FDA study of the CHARITÉ artificial disc for low 
back-pain compared artificial disc (experimental treatment) with another fusion 
technique (and not with the standard care).[39] 
Ethical lessons
In contrast to pharmaceuticals, where rigorous safety and comparative effectiveness 
research (multiple phases of RCTs) are required for approval, novel medical devices 
can be introduced in patients without sound evidence and with relatively little 
oversight and regulation in patients. The reluctance to set up surgical research 
and generate systematically collected evidence on the safety and effectiveness 
of devices is sometimes defended by ‘surgical exceptionalism’, the view that the 
somewhat exceptional ethical or regulatory status of surgery is justified by the 
unique dynamic nature of surgery.[40] There are several reasons why surgeons 
have taken this view. First, surgical techniques, unlike drugs, do not have chemical 
compositions, physical properties, routes and rates of excretion, or other qualities 
that can be measured precisely. Second, surgical procedures are rarely introduced 
as fully defined, easily reproducible techniques. Rather, they come as principles 
for solving particular problems, sometimes of an urgent nature.[41] Finally, in 
situations in which known interventions are of questionable value or where 
effective interventions do not exist, some state that a rigid regulatory paradigm 
cannot be applied to the innovative activities at the frontiers of surgical practice 
without adversely impacting the prospects for advancing the state of the art.[40] 
We partially adhere to surgical exceptionalism, accepting that surgery is sufficiently 
unique that it should not be governed by the same rules/requirements that apply 
in pharmaceuticals, but resisting that the entire domain of surgery (e.g. non-
acute diseases like LSS) would not be suitable for rigorous scientific evaluation 
of interventions.[40] The need for more rigorous evaluation of novel surgical 
procedures and medical devices is increasingly acknowledged in this era of 
evidence based medicine.[42–45] Furthermore, unnecessary and/or unproven 
treatments can harm patients and can be unnecessarily expensive for societies with 
growing health care expenditures. The dynamic nature of surgical practice does 
not preclude rigorous evaluation of new interventions in the surgical domain, and 
vice versa. It is a wide misunderstanding that if interventions do no good they will 
at least do no harm and therefore nothing would be lost – this ‘no lose philosophy’ 
has already been criticized in the 1970s.[46] 




Fifty percent of all new drugs have important side effects discovered only after 
approval and marketing.[6] Taking into account the statement of FDA officials that 
“New devices are less likely than drugs to have theirs safety established clinically 
before they are marketed”, the amount of side-effects caused by surgical innovation 
and devices is potentially even higher.[47] Medical devices are complex assemblies 
of multiple components, making it impossible to design an implantable device 
without risks or harms.[48] Since “implanted body parts cannot be recalled as easily 
as defective auto parts”, inadequately tested devices should be prevented from 
coming on the market, and systems for monitoring safety after a medical device 
is marketed should be implemented.[2,4] This is true in particular given the lack of 
informed decision-making for patients, who are commonly operated on without 
sufficient awareness of the potential harm of experimental implants, and given 
the substantial commercial interests and aggressive marketing tactics of large 
international producers of devices. 
Way forward for the introduction of spinal implants
The case study set out above gives strong arguments for introducing a stepwise 
approach to introducing new implant devices.[6,49] We limit our discussion of this 
approach to implant devices because of the large differences between various 
(types of ) medical devices, and their consequences for regulation in this field.[6,50] 
Several authors have made suggestions for what needs to be done to avoid harmful 
and costly mistakes as have occurred in the introduction of IPDs for LSS. In our 
view, two measures are most feasible in realizing a regulatory system that ensures 
that medical implant devices are safe and effective. First, prospective controlled 
trials that compare the experimental device to the present gold standard for that 
disease should be required for device approval. To be approved, the effectiveness of 
the new device should be at least equal or compared with the gold standard, and 
it should be safe. Second, a monitoring system (post-implementation registries) 
for all medical devices, as suggested by the European Committee, could help to 
trace these implants and ensure rigorous clinical follow-up. The establishment 
of registries would allow the collection of reliable data on adverse events and 
monitoring of long-term safety and efficacy.[2] By early detection of negative 
results the use of an implant could be stopped or modified in order to avoid further 
damage. Moreover, it will give a clear overview of the innovations present in the 
field, so other innovators are not likely to repeat failed surgical procedures with 
certain implants. 




Medical implant-devices are frequently introduced without adequate evidence 
of safety and efficacy. This results in harmful medical practices for patients. Steps 
should be taken to strengthen regulation for device development and introduction, 
without unnecessarily inhibiting R&D. Two measures are most feasible in the short-
term: (1) requiring prospective studies before device approval, and (2) developing 
registries in order to monitor and evaluate new medical devices and all surgical 
implants.
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Intermittent neurogenic claudication (INC) is a complex of symptoms caused by 
lumbar spinal stenosis (LSS). Symptoms include leg pain, numbness of  (frequently 
both) the legs and associated back pain. Usually patients will have a few months 
of conservative treatment before they are offered surgery. For over a century, bony 
decompression has been the gold standard. However, the present success rate 
of this gold standard is only 65%. New imaging techniques to improve patient 
selection and new treatment options to improve direct outcome have been 
developed. The main goal of new treatment options is to reduce the surgical extent 
in order to maintain the balance of the spine and to lower the risk of instability 
after the decompression. (Chapter 1) In 1986, a research group proposed a new 
technique in which an implant was placed between the spinous processes in order 
to indirectly decompress the spinal nerve roots and to unload the facet joints. Many 
similar devices have been developed over the past decades, but no biomechanical 
differences were demonstrated. Thousands of patients have since been implanted 
with these devices. Efficiency (not cost-efficiency) has only been demonstrated in 
comparison to conservative treatment. This thesis outlines the results of a double 
blind multicentre trial (the FELIX trial) in which an interspinous process device 
(IPDs) was compared with conventional bony decompression in the treatment of 
INC. Furthermore, we evaluated the diagnostic and prognostic value of MR images 
in patients with lumbar stenosis and INC.
Chapter 2 describes a national survey held among Dutch spine surgeons of their 
daily practice of patients with INC caused by LSS. The survey demonstrated a 
wide variety of Dutch spine surgeons’ preferred treatment of symptomatic LSS. 
To minimize variety, national and international protocols based on high-quality 
randomized controlled trials (RCT) and systematic reviews are necessary to give 
surgeons more tools to support everyday decision-making. Furthermore, over 30 
percent of Dutch spine surgeons used IPDs (outside study protocol) in treatment 
for patients with INC.
The existing evidence on interspinous implant surgery was systematically reviewed 
in chapter 3. This systematic review did not include the results of the Felix Trial, 
because the review was done in 2011 before the publication of the Felix Trial 
(2013). Two independent RCTs and eight prospective cohort studies on patients 
with INC caused by LSS were available. In total 563 patients treated with IPDs were 
included. All studies showed improvement in validated outcome scores (patient 
satisfaction, disease specific questionnaires and leg pain) after six weeks and one 
year. Pooled data of the RCTs were more in favor of IPD treatment compared with 




conservative treatment. Overall complication rate was 7%. The evidence presented 
in this systematic review was relatively low and the costs of the IPDs were high, 
which at that time were already widely used, therefore we needed more thorough 
(cost-) effectiveness data.
The design of the Felix Trial is presented in Chapter 4. The manufacturers of these 
new implants claimed that treatment with IPDs would give a faster recovery. 
Therefore, IPDs had to be superior at short-term (eight weeks) compared with (the 
gold standard) bony decompression. At least 160 patients had to be randomized. 
To enroll enough patients, fifteen hospitals participated in the study after approval 
of the protocol by the medical ethics committees.
The 1-year clinical results (presented in Chapter 5) did not show any benefit of 
treatment with IPD over bony decompression. This double-blinded study could 
not confirm the hypothesized short-term advantage of interspinous process device 
over conventional “simple” decompression. Furthermore, after 1-year significantly 
more patients were re-operated in the IPD group (29%) compared with the bony 
decompression group (8%). The subgroup analysis (Chapter 5) could neither 
assign any subgroup (such as elderly or obese people) which would benefit from 
treatment with IPDs.
The long-term (2-years) results were similar to the 1-year results (Chapter 6). The 
long-term follow-up did not show important differences in results (based on the 
ZCQ) comparing treatment with IPD and conventional bony decompression in 
patients with INC based on LSS. Furthermore, similar to the one-year analysis, the 
re-operation rate was significantly higher (overall and in the period between 52 and 
104 weeks) in the IPD group compared with the bony decompression group. Back 
pain was hypothesized to be less in the group that underwent an operation with 
less tissue damage, namely the IPD without bony decompression group. However, 
to the contrary, the long-term back pain in IPD group was significantly – though not 
clinically relevant – higher compared with the conventional bony decompression 
group. 
Chapter 7 describes the cost-benefit analysis of the Felix Trial. The economic 
evaluation showed less favourable QALY outcomes (not significant) after IPD. 
Healthcare costs were higher for IPD treatment compared with decompression. 
From a societal perspective the cost of IPD treatment were also higher, though not 
significant. Implantation of IPD is highly unlikely to be cost-effective compared with 
bony decompression for patients with INC caused by LSS. The use of these implants 
over the past three decades could therefore not be justified based on this study.
30142 Moojen.indd   163 12-09-14   10:27
Chapter 10
164
MRI evaluation (Chapter 8) showed good agreement on the clinically relevant level 
of lumbar spinal stenosis between experienced readers. However, MRI assessment 
of grading of compression did not correlate with baseline complaints of INC, nor 
with outcome after one year. However, both absence of epidural fat and presence 
of tortuous caudal nerves on MR images in patients with LSS were relatively good 
predictors for satisfactory recovery after surgery. MRI should therefore only be used 
to appoint the pathological level in case surgical decompression is considered.
Conclusions
The clinical introduction of novel medical devices, such as the introduction of IPDs, 
often occurs without high quality evidence and with little regulation compared to 
pharmaceutical interventions. As a consequence the safety, efficacy and long-term 
effects for patients are insufficiently guaranteed. IPDs heave been used for over 
thirty years, while good clinical data are becoming available only now. Treatment 
with IPD did not show any societal benefit though it is responsible for higher health 
care costs. The controversies surrounding the implementation of IPDs underscore 
the need to reconsider how innovation in medical devices and surgical techniques 
should adhere to sound ethical standards without inhibiting surgical research and 
development (Chapter 9). Ethical lessons should be learned from the history 
in the past thirty years of the introduction of various devices. There is no such 
thing as the ‘no lose’ philosophy: patients are harmed by new developments. We 
suggest that this might be prevented by demanding prospective studies upon 
device introduction, and by developing (European) registries in order to monitor 
and evaluate new medical devices.
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Neurogene claudicatio klachten (syndroom van Verbiest) is een verzameling van 
symptomen die veroorzaakt worden door degeneratieve lumbale kanaalstenose 
(door ‘slijtage’ versmalling van het kanaal waar de zenuwen doorheen lopen). Met 
de toenemende levensverwachting komt deze degeneratieve ziekte ook navenant 
meer voor: het is nu in West-Europa de ziekte met de meeste zorgbelasting voor de 
maatschappij. Het syndroom bestaat meestal uit beenpijn (meestal beide benen), 
doofheid (onstabiel gevoel) in beide benen en regelmatig ook geassocieerde rugpijn. 
vanaf de eerdere publicaties van de vorige eeuw wordt benige decompressie van 
het bot als gouden standaard gezien: verwijderen van de dorsale zijde (lamen/
boog) van het wervellichaam. Echter, deze gouden standaard heeft slechts een 
succespercentage van 65% na behandeling. In de afgelopen decennia zijn er 
voor de patiënt minder ingrijpende behandelingsmethoden ontwikkeld voor de 
patiënt. In 1986 (zie hoofdstuk 1) werd er door een onderzoeksgroep een nieuwe 
behandeling beschreven. Tussen de twee processus spinosi (achterste gedeelte 
van de wervel) van wervels plaatsten zij een implantaat dat de wervels ‘uit elkaar 
duwt’. Hierdoor wordt er op een gerichte plek indirect meer ruimte gegeven aan 
de zenuwen die door het wervelkanaal lopen. Daarnaast wordt met dit implantaat 
volgens de hypothese ook de gewrichten (facetten) ontlast. Daarna zijn er meerdere 
implantaten (in samenwerking met industrie) ontwikkeld. Deze implantaten blijken 
in biomechanische studies precies dezelfde eigenschappen te hebben. Mondiaal 
hebben honderdduizenden patiënten een dergelijk implantaat gekregen. Voor dit 
proefschrift waren bedoelde implantaten niet getest op (kosten)effectiviteit ten 
opzichte van de eerder beschreven gouden standaard. Dit proefschrift beschrijft de 
resultaten van onderzoek (FELIX studie) waarin behandeling met een implantaat 
(IPD) werd vergeleken met benige decompressie, waarbij patiënten via loting een 
behandeling toegewezen kregen (randomisatie). Patiënten en gespecialiseerde 
verpleegkundigen die de patiënten vergeleken en onderzochten wisten niet 
welke therapie, IPD of benige decompressie, de patiënt gekregen had (dubbel 
blind onderzoek). Daarnaast worden in dit proefschrift de resultaten van de MRI 
(waarop de mate van versmalling van het kanaal bepaald werd) gepresenteerd.
In hoofdstuk 2 worden de resultaten beschreven van een enquête die in 2011 
is ingevuld door leden van de Nederlandse vereniging van de wervelkolom 
geïnteresseerde chirurgen met hun ervaringen met het Verbiest syndroom. In 2011 
werden er in Nederland zeer veel verschillende behandelingstechnieken gebruikt. 
Bovendien bleek dat 30% van de wervelkolom centra deze IPDs gebruikte buiten 
studies in 2011 (dus voor de publicatie van de FELIX studie). Deze aangetoonde variëteit 




(praktijkvariatie) vraagt om meer protocollen en meer kwalitatief goede vergelijkende 
studies van de verschillende behandelingstechnieken die gebruikt worden.
In hoofdstuk 3 worden de resultaten van een systematische literatuurstudie 
gepresenteerd (van voor deze studie). In de periode tot 2011 waren er twee 
vergelijkende studies waarin IPD behandelingen werden vergeleken met 
conservatieve behandeling (geen operatie of injecties) en er was een achttal 
beschrijvende studies die een groep patiënten (behandeld met een IPD) volgden 
door de tijd. Er was over het geheel een 7% kans op complicaties. Behandeling met 
IPD was inderdaad beter dan geen behandeling, maar vergelijkende studies met 
de gouden standaard waren er tot dusverre niet.
In hoofdstuk 4 wordt het protocol van de FELIX studie besproken. De 
veronderstelling bij de IPD behandelmethode is dat zij vooral sneller een beter 
resultaat geven, want een IPD implantatie zou een minder ingrijpende operatie 
zijn. Daarom gaat het onderzoek er vanuit dat de patiënten die loten voor IPD 
een beter herstel hebben na acht weken in vergelijking met de patiënten die 
loten voor de standaard benige decompressie. Om een verschil tussen beide 
behandelingsmethodes betrouwbaar te kunnen aantonen hebben we een 
onderzoekspopulatie van 160 patiënten nodig met klachten van neurogene 
claudicatio en aangetoonde lumbale kanaalstenose op de MRI. De studiepatiënten 
werden twee jaar vervolgd. De studie werd goedgekeurd door de ethische 
commissie van de vijftien deelnemende ziekenhuizen.
De resultaten na één jaar laten geen positiever effect zien van behandeling met een 
IPD ten opzichte van de behandeling met de benige decompressie (hoofdstuk  5). 
Evenmin werd met deze dubbelblinde studie het aangenomen voordeel van 
behandeling met een IPD ten opzichte van behandeling met benige decompressie 
aangetoond. Bovendien was het heroperatiepercentage veel hoger in de IPD groep 
(29% werd opnieuw geopereerd) ten opzichte van de benige decompressie groep 
(slechts 8% kreeg een tweede operatie). Ook analyse op vooraf bepaalde factoren 
als leeftijd gaf geen subgroep waarbij behandeling met een IPD een betere resultaat 
opleverde dan de gouden standaard (benige decompressie). 
Op langere termijn ware de resultaten vergelijkbaar (hoofdstuk 6). Er was geen 
verschil tussen beide groepen. Bovendien was het aantal heroperaties in de IPD 
groep toegenomen. De veronderstelling dat de implantaten minder druk op de 
facetten zouden geven en daarmee ook minder rugpijn op de langere termijn ten 
opzichte van benige decompressie, bleek niet op te gaan. In de IPD groep was de 
rugpijn (na twee jaar) zelfs heftiger dan in de benige decompressiegroep. 
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Ook het verschil in kosteneffectiviteit is in de analyse beoordeeld (hoofdstuk 7). De 
IPD groep had een lagere QALY (maat voor kwaliteit uitgedrukt in geld per gezond 
levensjaar) in vergelijking tot de benige decompressiegroep. De kosten voor de 
gezondheidszorg zijn ook groter in de IPD groep en van een maatschappelijk 
perspectief waren de kosten (niet significant) hoger. Daarom valt niet aan te 
nemen dat het implanteren van IPD kosteneffectief is, dit nog los van de prijs die 
de industrie voor een dergelijk implantaat vraagt. Het gebruik van implantaten is 
daarom niet te verantwoorden. 
De uitslagen van de MRIs (hoofdstuk 8) toonde een vergelijkbare uitkomst tussen 
de beoordelaars (goede correlatie). Echter, de mate van compressie vertoonde 
geen correlatie met de mate van stenose op het moment dat de MRI gemaakt 
werd. Bovendien is de mate van stenose ook geen voorspeller voor de mate van 
herstel na een eventuele operatie. Alleen als er bij patiënten op de MRI een zeer 
nauw kanaal (de zenuwen liggen ‘opgekruld’ of al het normaliter aanwezige vet 
om de zenuwen is verdwenen) zichtbaar is, dan kan deze bevinding een goede 
uitkomst na chirurgische behandeling voorspellen.
Conclusie:
Sinds de tweede helft van de jaren ’80 zijn medische implantaten, zoals IPDs 
en PIP borstimplantaten, als behandelmethode geïntroduceerd, echter, zonder 
wetenschappelijk overtuigende onderbouwing dat deze behandelmethode 
betere resultaten opleverde. Er is overigens weinig (internationaal) toezicht op 
de introductie van implantaten in het algemeen. Hierdoor is vaak onduidelijk 
voor de clinicus en burger hoe veilig en/of effectief een implantaat is. IPDs zijn 
meer dan 30 jaar zonder goed wetenschappelijk bewijs geïmplanteerd bij 
patiënten over de gehele wereld. Het onderzoek in dit proefschrift levert geen 
wetenschappelijk onderbouwing voor de veronderstelling dat gebruik van IPDs een 
superieur behandelresultaat oplevert ten opzichte van de ‘benige decompressie’ 
behandelmethode. Verder maakt dit proefschrift duidelijk dat gebruik van IPDs 
als behandelmethode alleen maar kostbaar is geweest voor de gezondheidszorg 
en de maatschappij. Als beroepsgroep moeten de medische stand zorgen dat 
de implementatie van nieuwe implantaten en technieken veiliger wordt, zonder 
dat vooruitgang wordt belemmerd (hoofdstuk 9). Ethisch moeten we ook hier 
ook bij stilstaan, want bij gebruik van behandelmethodes geldt niet: “baat het 




niet, schaadt het niet”. Uitkomst van  dit proefschrift is om vóórafgaand aan de 
introductie van een implantaat te eisen dat  prospectieve studies aantonen dat het 
te introduceren implantaat positieve resultaten oplevert. Daarnaast adviseren wij 
het instellen van (Europese) registraties om na introductie een implantaat de lange 
termijneffecten te volgen. Daarnaast moet de wetenschappelijke gemeenschap 
ook van onderzoeksgroepen eisen dat deze eerst vergelijkende studies doen, 
voordat experimentele therapie wordt toegepast op patiënten.
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